SYSTEMS AND METHODS FOR GENETIC SEQUENCING
A device including a transparent layer defining a surface exposed to a flow volume and to secure a target polynucleotide template and a detector structure secured to the transparent layer and including a plurality of detectors to detect a signal emitted during nucleotide incorporation along the target polynucleotide template.
This application is a continuation under 35 U.S.C. § 120 of pending U.S. application Ser. No. 14/779,532 filed Sep. 23, 2015, which is a U.S. National Phase Application under 35 U.S.C. § 371 of International Application No. PCT/US2014/032604 filed Apr. 2, 2014, which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Nos. 61/835,428 filed Jun. 14, 2013 and 61/808,105 filed Apr. 3, 2013. The entire contents of the aforementioned applications are incorporated by references herein.
FIELD OF THE DISCLOSUREThis disclosure, in general, relates to systems and methods for genetic sequencing.
BACKGROUNDIncreasingly, genetic sequencing is being utilized in research and medicine. In particular, genetic sequencing is used to characterize, analyze, and manipulate characteristics of plants, for example, to improve productivity of food crops. Further, genetic sequencing is used in efforts to classify and characterize animals, including researching animal migration and species branching. In another example, genetic sequencing is used in medical research to identify genetic-based diseases, classify patient response to medicine or treatment, or determine characteristics indicating susceptibility to disease.
While many techniques are available for performing genetic sequencing, conventional techniques utilize extensive sample preparation, increasing costs associated with labor and consumables and introducing human error. Other techniques utilize large and expensive systems, increasing costs and lab space utilized by such techniques.
SUMMARYIn an embodiment, a system for genetic sequencing includes an integrated device having detectors for detecting signals indicating incorporation of a nucleotide during template-dependent nucleic acid synthesis along a target polynucleotide. The integrated device can further include a surface to which the target polynucleotide can be associated and defining a wall of a flow volume. The integrated device can further include an energy propagation layer or one or more filter layers. The system can include a fluidics system and a computational system in communication with the integrated device.
A method of genetic sequencing can include flowing nucleotides through a flow cell of an integrated device that includes detectors for detecting signals from the template-dependent incorporation of a complementary nucleotide. In some embodiments, the nucleotide includes an optically detectable label, and the method can further include providing excitation energy to the integrated device, the excitation energy either exciting a donor particle or molecule that energizes or excites the optically detectable moiety. Signals emitted during nucleotide incorporation are detected by the detector, leading to a determination of base identity for the incorporated nucleotide.
The present disclosure may be better understood, and its numerous features and advantages made apparent to those skilled in the art by referencing the accompanying drawings.
The use of the same reference symbols in different drawings indicates similar or identical items.
DETAILED DESCRIPTIONIn an exemplary embodiment, a target polynucleotide is linked to a surface of a device and is exposed to nucleotides, such as labeled nucleotides. Signals indicative of nucleotide incorporation are detected by detectors integral to the device. Exemplary detectors can be pH sensors, heat detectors, photon detectors, or combinations thereof. The target polynucleotide can be linked to the surface directly or indirectly. For example, the target polynucleotide can couple with a probe bound to the surface or can be captured by an enzyme secured to the surface. In some embodiments, labels of labeled nucleotides fluoresce upon incorporation along the target polynucleotide, providing a fluorescent signal to be detected by detectors integral to the device.
In some embodiments, the disclosure relates generally to methods, as well as related compositions, systems, apparatuses and devices, for contacting a device with an enzymatic reaction, where the enzymatic reaction comprises a nucleic acid sequencing reaction. The nucleic acid sequencing reactions include any type of template-dependent sequence-by-synthesis method, including transient-binding reactions, optically-detectable reactions, energy transfer reactions (e.g., FRET), and dark nucleotide reactions (non-labeled nucleotides). In some embodiments, the device comprises an integrated device having detectors that detect signals from a nucleotide incorporation reaction, including any device described herein.
In an exemplary embodiment, a system includes an integrated device for detecting signals, e.g., fluorescence signals, indicative of nucleotide incorporation. In some embodiments, when a complementary optically labeled nucleotide is hybridized to, or is incorporated along a target polynucleotide, the label can emit an optically detectable signal. The signal from the label can be detected and used to determine base identity of the incorporated nucleotide. The system can include a fluidics system for feeding nucleotide solutions to the integrated device and can include computational systems for controlling the integrated device and for gathering data from the integrated device. The integrated device can further include a surface proximal to which a nucleotide is incorporated, for example, to extend a primer complementary to a target polynucleotide. The integrated device can further include detectors for detecting signals indicative of the nucleotide incorporation. Such signals can be emitted, for example, from fluorescent labels coupled to nucleotides to be incorporated and can result from fluorescence resonance energy transfer (FRET)-based fluorescence. Optionally, the integrated device can further include energy propagating layers for transferring energy to donors or a fluorescent dye, layers for filtering light to provide selectivity for a desired wavelength, and a lid to define a flow volume through which nucleotide solutions flow. Layers can include one or more substantially planar structures formed of materials having a desired physical, chemical, or optical property.
In an exemplary method, an integrated device is inserted into a system and coupled to communicate with a computational system and in fluid communication with a fluidics system. A target polynucleotide is applied at surface locations within the integrated device. Solutions including nucleotides modified with fluorescent dye are provided through the fluidics system to the integrated device. Fluorescent signals resulting from incorporation of nucleotides complementary to a target polynucleotide are measured by detectors forming a portion of the integrated device. Detected fluorescence is accessed by the computational device for further analysis.
In an example,
The integrated device 102 can also be in communication with a controller 120 and an analyzer 118 of the computational systems 116. In addition, the computational systems 116 can include other processing systems 124 and interfaces 126, such as network interfaces and user interfaces. The computational systems 116 can be integrated into a single unit. Alternatively, the computational systems 116 can be remote from the remainder of the system, operating on a network, cloud, or other grouping of computational devices. In a further example, the controller 120 or other control circuitry can control temperature, wavelength fluorescent excitation power, pressure or other parameters.
The system 100 can further include an excitation source 106 to provide excitation energy 108 to the integrated device 102. For example, the excitation source 106 can provide laser light or electromagnetic energy to one or more layers of the integrated device 102. Such excitation energy 108 can provide energy to fluorescent dye or energy donors. Alternatively, such energy sources can be integrated into the integrated device 102. In a particular example, the controller 120 is in communication with the excitation device 106 and controls excitation of the integrated device 102 to selectively periodically excite donor particles or a dye, which provides energy to be emitted in response to nucleotide incorporation. In an example, the controller 120 can communicate both with the excitation source 106 and the integrated device 102 to provide fluorescent lifetime imaging. In another example, the excitation source 106 can interface with the integrated device 102 using a fiber optic faceplate. The excitation source 106 can be formed of light emitting diode (LED), such as an organic light emitting diode (OLED), or a LED of specific wavelength, such as a blue LED.
In a particular example, the reagent solutions 114 can include a wash solution, and a solution including four types of modified nucleotides, each type of nucleotide optionally modified with a different label having a different emission spectrum. The nucleotide solution can be applied to the integrated device 102. As nucleotides are incorporated to extend a primer complementary to the target polynucleotide, signals are emitted in a wavelength spectrum that corresponds with the incorporated nucleotide. The spectrum can be a narrow set of wavelengths or can be a set of wavelengths emitted by a dye or dyes associated with a type of nucleotide. Detectors within the integrated device 102 detect the signal and provide a series of signals to the analyzer 118 and other processing 124 to determine the sequence of one or more nucleotide bases that are incorporated to the extending nucleic acid molecule.
In another example, the reagent solution containers 114 can include a wash solution and a plurality of solutions that each includes a type of dye modified nucleotide, wherein each type of nucleotide is modified with a dye having the same or a different emission spectrum. The nucleotide solutions can be fed to the integrated device 102 sequentially. Fluorescent signals emitted as a result of nucleotide incorporation can be detected by detectors within the integrated device 102. Data associated with a series of detections can be provided to the analyzer 118 and other processing 124 for determining genetic sequence information.
In a particular example, a target polynucleotide is linked, directly or indirectly to a surface. Labeled nucleotides provide a signal upon incorporation that is detected by the integrated device 102 and provided to the analyzer 118. For example, a donor molecule or particle, such as a quantum dot (Qdot) nano-crystal, can be tethered to an enzyme, such as a DNA polymerase, without changing the functional properties of the enzyme. The donor molecule or particle absorbs light from a laser excitation source (e.g., source 106 or a source integrated with the device 102) and conditionally transfers energy to a labeled nucleotide depending on an incorporation event. Each of four nucleotides is terminally labeled with one of four different organic florescent dyes. Strands of the target polynucleotide are immobilized on a surface while the donor molecule or particle labeled enzyme binds to the primer-target complexes. The nucleotides are added to start the synthesis of DNA. When a nucleotide binds to the enzyme, due to close proximity to the donor molecule or particle, resonance energy is transferred to the nucleotide dye, which then emits its own light, for example, in the 600 nm-800 nm range. The light is collected and optionally spectrally separated and detected by one or more detectors associated with the location of the immobilized target polynucleotide. The label of the labeled nucleotide can be cleaved when the enzyme incorporates the nucleotide. Since the energy transfer occurs in the vicinity of the donor molecule or particle, the signal is spatially confined to the enzyme and the nucleotides in solution are rarely caused to emit light. This spatial separation of emissions keeps the background noise low. A second signal that indicates base incorporation comes from a measured decrease in intensity from the donor molecule or particle itself as it transfers energy to the nucleotide label.
In an exemplary embodiment, various features of the stimulation and detection system are integrated to increase performance and lower the cost of the system. The system is highly scalable, potentially achieving billions of simultaneous single molecule DNA sequencing runs on a single low cost substrate.
In an example, a functional semiconductor substrate is fabricated using complementary metal oxide semiconductor (CMOS) processing. Various implants are used to form photodiodes and transistors specific for detecting the incorporation events that can occur at very low intensity. When photons from the incorporation event fall onto the CMOS substrate, electron-hole pairs are created. In the case of a p-type substrate, holes are drained into the substrate, while the electrons are confined in potential wells until they are readout by proper circuitry containing transistors, electrodes or relevant parasitic structures. Although electron confinement is discussed, all similar principles are applied to hole confinement and readout. In a particular example, electron-hole pairs can be created at a depth in the silicon substrate that is dependent on wavelength of the radiation. For example, blue photons create electron-hole pairs near the surface of the silicon, while red photons create a majority of electron-hole pairs deeper than a few microns into the substrate. In an embodiment described in more detail below, a single pixel can be created in close proximity to the polymerase in which the “color” of the light can be differentiated by using multiple confinement wells at different depths within the substrate. For example, the single pixel can include at least two confinement wells, such as at least three confinement wells, but generally less than 10 confinement wells. The confinement wells can have a depth of not greater than 5 micrometers, such as not greater than 3 micrometers. In particular, a shallow confinement well can be centered around 1 micrometer depth and a deep confinement well can be centered around 2 micrometers depth. The number of electrons captured in each confinement well indicates which base is incorporated. The confinement well for the secondary signal (photons coming directly from the Qdot) can also be designed with selective sensitivity, most likely near the surface. A well capacity for the secondary signal can be created specifically for the parameters of the system. The wavelengths using the high levels of sensitivity can be designed to reduce surface states. If the secondary signal is large relative to the colored signals, a surface diode can be used, which normally has a higher dark current level, but is acceptable for sufficiently large signals. The other confinement wells can be “buried” with pinning implants to eliminate surface defect induced dark current. A CCD collection electrode may also be combined along with photodiode implants, creating a hybrid CCD/photodiode pixel. Such a configuration has advantages when different well capacities are used between the primary and secondary signals.
Optionally, the integrated device 200 includes an energy propagation layer 210, such as a layer that provides for total internal reflection (TIRF) or that provides for energy propagation creating an evanescent wave proximal to the target polynucleotides 220. In an example, the energy propagation layer 210 propagates energy, such as photonic energy, along a path that is generally parallel (e.g., TIRF) to the surface 212. In a particular example, an evanescent wave is produced by the propagation of energy in the energy propagation layer 210. The energy propagation layer 210 can include a transparent layer through which light or other electromagnetic energy is transmitted. Such a transparent layer can be formed of a transparent ceramic, such as silicon dioxide or indium tin oxide, or can be formed of a transparent polymer, such as a polycarbonate or a transparent fluoropolymer. In another example, the energy propagation layer can be formed of a material conducive to carrying electromagnetic energy in a plane parallel to the surface layer 212. Such materials can include thin conductive layers, such as metal layers. In an alternative example, the surface layer 212 forms the energy propagating layer and total internal reflection is caused by a difference in the index of refraction between an aqueous solution and the layer (212 or 210). In a further alternative, an excitation energy source can be disposed above the target polynucleotide 220.
The device 200 can further include a layer 208 to facilitate total internal reflection within the energy propagation layer 210. The layer 208 can be reflective to wavelengths associated with the excitation energy propagated through the energy propagation layer 210. In another example, the layer can have an index of refraction different from that of the energy propagation layer 210 and causing reflection of the propagating energy at particular incident angles.
In another example, the integrated device 200 can include a layer 206 to filter excitation energy propagating within the layer 210. In particular, the filter layer 206 can include materials that selectively permit transmission of wavelengths associated with fluorescent signals from dye of the modified nucleotides, but are at least partially opaque to wavelengths associated with excitation energy. For example, the filter layer 206 can include GaAs, polysilicon, CdS, CdSe, or a combination thereof.
In an additional example, the integrated device 200 can include a filter layer 204 to further filter fluorescent signals resulting from nucleotide incorporation into component spectra to be detected by detectors within the layer 202. An exemplary filter layer material includes doped silicon dioxide, doped zirconia, or another predominantly transparent material doped with a coloring agent.
Optionally, crosstalk prevention structures 222 can be provided that extend through one or more layers towards the energy propagation layer 210, defining pixels and preventing crosstalk of fluorescent signals between pixels. The crosstalk prevention structures 222 can extend through the filter layers, such as filter layers 204 or 206, and optionally within the substrate 202.
During operation, solutions including one or more nucleotides modified with fluorescent dyes can flow through the flow volume 224 and may or may not be incorporated to extend a primer along a target polynucleotide 220. Excitation energy can be provided through the energy propagation layer 210 which excites the fluorescent dye or optionally donor particles in proximity to fluorescent dye being incorporated along the target polynucleotide 220. During incorporation, the fluorescent dye of modified nucleotides fluoresces, and such fluorescence is detected by detectors within the substrate 202. Optionally, excess excitation energy is filtered by filter layer 206 and the fluorescence can be separated into different spectrum by the filter layer 204 to be detected by different detectors formed within the substrate 202. While the filter layer 206 for filtering excitation energy is illustrated as being further from the detector than the filter layer 204, the position of such filter layers can be reversed when both are included within the integrated device 200. Fluorescent signals from adjacent wells or regions on the surface structure 212 can be blocked by the crosstalk prevention structures 222.
In operation, nucleotide solutions including nucleotides modified with fluorescent dyes flow through the flow volume 324 and may be incorporated into or along a polynucleotide target 320. The dye associated with the nucleotide can be energized by a donor particle that is energized by an evanescent wave or can be energized by the evanescent wave itself. The evanescent wave can be provided by the energy propagation layer 314. Fluorescent signals resulting from the incorporation of the nucleotide along the target polynucleotide 320 can pass through the flow cavity 324 and the lid layer 308 and optionally through filters 304 or 306 for filtering excitation energy and separating fluorescence into various detectable spectrums by the detectors defined within the layer 302. Fluorescence from adjacent target polynucleotides can be prevented from impinging on other detectors by the crosstalk prevention structures 322.
The crosstalk prevention structures, such as 222 or 322, can be formed of reflective material or material that is opaque to the wavelength of excitation energy or the fluorescence spectra. For example, the crosstalk prevention structures 222 or 322 can be formed of metal, such as aluminum, copper, titanium, gold, silver, platinum, or any combination thereof. In another example, the crosstalk prevention structures 222 or 322 can be formed of polysilicon or doped polysilicon having a thickness sufficient to limit transmission of photons across the structure 222 or 322. When the optical detectors are electronic in nature, the crosstalk prevention structures can also be insulative.
As illustrated in
As illustrated in
For example,
Similarly,
While
In an example, one or more layers can be provided that filter specific wavelengths from the emitted signal. In such an example, generic detectors can be utilized underlying different filters and resulting in the detection of different wavelengths of light within the various detectors. In particular example, layers of various thickness of material that is semi-opaque to fluorescence emitted by the fluorescent dyes can be utilized to filter fluorescent light before it impinges various detectors. For example, as illustrated in
In a particular example, the thickness of the polysilicon is adjusted for each color. For example, a thick polysilicon layer absorbs blue and green but may allow the majority of red photons to pass through. A pixel with no polysilicon layer may allow all colors to pass through. In the simplest form, two pixels, one containing a polysilicon layer and one without a polysilicon layer, can be used to differentiate four different nucleotide incorporation events. These absorption layers can be implemented at the silicon substrate or after backend metal layers are processed along with the dielectric layers. Employing absorption layers in both the frontend of the process and the backend of the process gives additional options for selectivity.
In an alternative example, illustrated in
In an alternative example, the deep implant 1508 is not self aligned with the polysilicon and is made with a single energy and dose. The native p-epitaxy region 1510 forms the barrier between the shallow junction and a narrow junction. The pixel is read with the shallow junction first being fully depleted before the deep junction charge is transferred. A p-type implant 1506 at an electrode 1518 creates a sufficient barrier to prevent charge transfer from the deep junction to the floating diffusion 1512. Since the epitaxy region 1510 is lightly doped, it is depleted easily to the depth of the deep implant 1508. When the electrode 1516 is switched to high potential, the electrons in the deep implant are transferred to the floating diffusion 1514. Consequently electrons in the shallow junction 1504 may also be transferred during the cycle. For this reason, the shallow junction should be empty first. Alternatively, the shallow junction can be pulled back sufficient distance from the electrode 1516, which may decrease the quantum efficiency of the shallow junction.
Since the incorporation events occur asynchronously over the course of the DNA synthesis, a high frame rate is used to capture incorporation events. It is advantageous to reduce the data at each incorporation site to build high density systems. The data at each site can be limited to the color of the nucleotide and whether or not the event is a true incorporation, utilizing 3 bits. For example:
000—no incorporation
001—no incorporation
010—no incorporation
011—no incorporation
100—Red labeled nucleotide
101—Orange labeled nucleotide
110—green labeled nucleotide
111—yellow labeled nucleotide
A mapping of these bits to the depth of the confined photo charge within two confinement wells can be used with the confinement wells illustrated, for example, in
In addition or alternatively, the system can include filters that filter fluorescence into various wavelengths to be provided to different detectors. Although the spectral content of the primary signal can be separated by confining the photogenerated electrons at multiple depths within silicon, other methods may also be effective. Pigment or dye based organic color filters can be patterned above each pixel using photolithography methods. At least two different colors can be used to differentiate between four labeled nucleotides. Absorption filtering may also be effective by fabricating polysilicon layers above each pixel as shown above in
An additional filter layer can be provided that filters excitation energy but permits the wavelength spectra emitted from fluorescent dye to pass through the filter. For example,
Optionally, a microlens configuration can be utilized to focus emitted fluorescence onto detectors. For example, the integrated device can include a layer incorporating microlenses. As illustrated in
Energy propagation layers that provide total internal reflection of excitation energy can be used to provide an evanescent wave within the solution. Such evanescent waves can energize donors which donate energy to fluorescent dye or can energize the fluorescent dye itself. In a particular example, excitation light can be received from an external source. For example, as illustrated in
In another example illustrated in
In a further example, an energy source, such as a light emitting diode (LED) or other energy source, can be integrated within the device. For example, as illustrated
In a particular example, light emitting diodes (LEDs) are created at each pixel location working on the principle of hot carrier direct recombination. The light source is modulated in conjunction with the readout of the photodiodes to tune the system for response. Since the light source can be bound to the silicon substrate, and local to the incorporation site, the donor molecule or particle may be removed, because the light source interacts with the labeled nucleotides that are bound to the polymerase during the incorporation, keeping the background noise low, while simplifying the system. The light source can be constantly modulated while the photodiodes are readout during the off-cycles. If a label lights up and is detected by the pixels at the incorporation site, it most likely comes from a nucleotide that is incorporated into the DNA. Therefore, if the polymerase is bound to the pixel and the light source is local to every pixel, then direct stimulus of the labeled nucleotide can be used and effectively detected.
In a further alternative illustrated in
In a further alternative, excitation energy can be provided from an external source directly to the donor particles or dye without propagating to a detector. For example,
In another example, when a wave or energy propagation layer is utilized, additional structures can be formed proximal to the energy propagation layer to enhance the evanescent wave within particular regions. For example, conductive structures can be formed that provide edges and points configured to enhance or concentrate such evanescent waves within small regions. As illustrated in
Many types of florescent labels may be used and some may have advantages over others depending on the stimulator that is integrated within the silicon substrate. For example, a local RF signal may be generated at each incorporation site. The RF power may be absorbed by the label and emitted as visible light sensed by the detection pixels.
A target polynucleotide can be localized, linked or otherwise secured to a surface such as through hybridization to a complementary primer, or can be captured by an enzyme secured to the surface. The surface can be formed of transparent or semitransparent material permitting the transmission of fluorescent emission to a detector. In an example, the flow of target polynucleotides into regions to be detected can be controlled by electromagnetic potential or charge. In an example illustrated in
As illustrated in
In another example, pad regions can be formed on a surface to which polynucleotides or enzymes can be selectively attached. As illustrated in
Depending on the nature the system, the template polynucleotide can be linked (e.g., covalently or non-covalently) to the surface. Alternatively, an enzyme (e.g., a polymerase or other template-binding enzyme) can be tethered to the surface and can capture polynucleotides. In FRET-based systems, the enzyme can be associated with a donor particle. For example, as illustrated in
In a further example illustrated in
Surface binding of the template polynucleotide or of the enzyme can be facilitated using a molecular recognition layer bound to the surface. The surfaces to which the molecular recognition layer is bound can be treated with a layer of chemicals prior to attaching probes to enhance the binding or to inhibit non-specific binding during use. For example, glass surfaces can be coated with self-assembled monolayer (SAM) coatings, such as coatings of as aminoalkyl silanes, or of polymeric materials, such as acrylamide and proteins.
Probes can be attached covalently. A number of different chemical surface modifiers can be added to the surface to attach the probes. Examples of chemical surface modifiers include N-hydroxy succinimide (NHS) groups, amines, aldehydes, epoxides, carboxyl groups, hydroxyl groups, hydrazides, hydrophobic groups, membranes, maleimides, biotin, streptavidin, thiol groups, nickel chelates, photoreactive groups, boron groups, thioesters, cysteines, disulfide groups, alkyl and acyl halide groups, glutathiones, maltoses, azides, phosphates, and phosphines.
In some embodiments, surfaces that are reactive to probes comprising amines are used. Examples of such surfaces include NETS-esters, aldehyde, epoxide, acyl halide, and thio-ester. Most proteins, peptides, glycopeptides, etc. have free amine groups, which react with such surfaces to link them covalently to these surfaces. Nucleic acid probes with internal or terminal amine groups can also be synthesized. Thus, nucleic acids can be bound (e.g., covalently or non-covalently) to surfaces using similar chemistries.
The surfaces to which the probes are bound need not be reactive towards amines, but can be easily converted into amine-reactive surfaces with coatings. Examples of coatings include amine coatings (which can be reacted with bis-NHS cross-linkers and other reagents), thiol coatings (which can be reacted with maleimide-NHS cross-linkers, etc.), gold coatings (which can be reacted with NETS-thiol cross linkers, etc.), streptavidin coatings (which can be reacted with bis-NHS cross-linkers, maleimide-NHS cross-linkers, biotin-NHS cross-linkers, etc.), and BSA coatings (which can be reacted with bis-NHS cross-linkers, maleimide-NHS cross-linkers, etc.). Alternatively, the probes, rather than the open surface, can be reacted with specific chemical modifiers to make them reactive to the respective surfaces.
A number of other multi-functional cross-linking agents can be used to convert the chemical reactivity of one kind of surface to another. These groups can be bifunctional, tri-functional, tetra-functional, and so on. They can also be homo-functional or hetero-functional. An example of a bi-functional cross-linker is X—Y—Z, where X and Z are two reactive groups, and Y is a connecting linker. Further, if X and Z are the same group, such as NETS-esters, the resulting cross-linker, NHS—Y—NHS, is a homo-bi-functional cross-linker and would connect an amine surface with an amine-group containing molecule. If X is NETS-ester and Z is a maleimide group, the resulting cross-linker, NHS-Y-maleimide, is a hetero-bi-functional cross-linker and would link an amine surface (or a thiol surface) with a thio-group (or amino-group) containing probe. Cross-linkers with a number of different functional groups are widely available. Examples of such functional groups include NETS-esters, thio-esters, alkyl halides, acyl halides (e.g., iodoacetamide), thiols, amines, cysteines, histidines, di-sulfides, maleimide, cis-diols, boronic acid, hydroxamic acid, azides, hydrazines, phosphines, photoreactive groups (e.g., anthraquinone, benzophenone), acrylamide (e.g., acrydite), affinity groups (e.g., biotin, streptavidin, maltose, maltose binding protein, glutathione, glutathione-S-transferase), aldehydes, ketones, carboxylic acids, phosphates, hydrophobic groups (e.g., phenyl, cholesterol), etc. Such cross-linkers can be reacted with the surface or with the probes or with both, in order to conjugate a probe to a surface. Other alternatives include thiol reactive surfaces such as acrydite, maleimide, acyl halide and thio-ester surfaces.
Such surfaces can covalently link proteins, peptides, glycopeptides, etc., via a (usually present) thiol group. Nucleic acid probes containing pendant thiol-groups can also be easily synthesized.
Alternatively, one can modify surfaces with molecules such as polyethylene glycol (PEG), e.g. PEGs of mixed lengths. Other surface modification alternatives (such as photo-crosslinkable surfaces and thermally cross-linkable surfaces) can be used.
The examples of
In another example, beads or particles can be used to deposit capture molecules at locations, limiting depositions over a pixel by size exclusion based on the size of the bead. Such limited deposition can be used with the device of
In another example, the length of a signal indicative of a nucleotide that is next in the sequence can be extended by capturing the nucleotide and causing it to emit the signal while preventing incorporation of the nucleotide. In an example, an inhibiting agent can prevent incorporation of the modified nucleotide. An exemplary inhibiting agent includes divalent metal ions, such as calcium, scandium, titanium, vanadium, chromium, iron, cobalt, nickel, copper, zinc, gallium, germanium, arsenic, and selenium ions. In another example, functionality on the nucleotide can prevent incorporation of the modified nucleotide.
In either case, the enzyme can capture the next complementary nucleotide. Modified functionality of the nucleotide can emit a signal, such as a fluorescent signal. As a result of inhibiting the incorporation of the modified nucleotide, the length of the signal can be extended. Subsequently, a complementary nucleotide can be incorporated along the sequence. For example, the inhibiting agent can be washed away, permitting incorporation of the modified nucleotide. In another example, a complementary nucleotide modified with functionality to prevent incorporation can be washed away and replaced with a similar modified nucleotide having functionality that permits incorporation.
In an example, modified nucleotides can be provided sequentially. In another example, the modified nucleotides can be provided in groups of two, three, or four types of nucleotides. For example, when nucleotides are supplied separately and sequentially, the functionalities modifying the nucleotides can provide a similar signal, such as a similar wavelength of emission. Such signals, when the modified nucleotides are incorporated, are separated by time allowing identification of the nucleotide.
For example, as illustrated in
Alternatively, each type of nucleotide (e.g., A, T, C, or G) can be modified to emit a different signal, such as a signal of a different wavelength. For example, when two types of modified nucleotides flow together through a flow cell, each of the two types of modified nucleotides can be modified with a functionality that emits a different wavelength from the other type of modified nucleotide. As such, the nucleotide being incorporated can be identified based on the different wavelength of emissions, for example. In an example, when a modified A-type nucleotide is provided simultaneously with a modified T-type nucleotide, the modified A-type nucleotide can be modified to provide a distinctly different wavelength from the modified T-type nucleotide. Similarly, when C and G-type modified nucleotides are supplied together, each type of modified nucleotide can include functionality that emits at a different wavelength from the other type of nucleotide.
In a further example, four types of modified nucleotide can be provided in solution simultaneously. In such an example, each of the modified types of modified nucleotides can emit different signals, such as that at different wavelengths. Alternatively, one type of nucleotide (i.e., a dark nucleotide) of the four may not be modified to emit a signal. In such an example, the inhibiting agent can be intermittently fed to the flow volume to inhibit incorporation and increase the signal length of the nucleotide to be incorporated. When the inhibiting agent is removed from the chamber, incorporation can proceed. In another example, one incorporatable modified nucleotide can be fed to the flow volume simultaneously with three other unincorporatable modified nucleotides. Solutions including a select incorporatable modified nucleotide (e.g., A, T, C or G) can be fed simultaneously to the flow volume with three other unincorporatable types of modified nucleotides. Such solutions can be fed sequentially or one after the other.
In another example illustrated in
In a further example illustrated in
Modified nucleotides can be labeled or modified to provide the ability to provide a signal in response to incorporation and optionally, to adjust whether the nucleotide or analog thereof can be incorporated.
In one embodiment, the labeled nucleotide can include 3-10 or more phosphate groups. In an example, the labeled nucleotide can be adenosine, guanosine, cytidine, thymidine or uridine, or any other type of labeled nucleotide. In another example, the label can be an energy transfer acceptor reporter moiety. In particular, the label can be a fluorescent dye. The polymerase can be contacted with more than one type of labeled nucleotide (e.g., A, G, C, or T/U, or others). Each type of labeled nucleotide can be operably linked to a different reporter moiety to permit nucleotide identity. Each type of labeled nucleotide can be operably linked to one type of reporter moiety. In an example, the labeled nucleotides are operably linked at the terminal phosphate group with a reporter moiety. In another example, the labeled nucleotides are operably linked at the base moiety with a reporter moiety. In another embodiment, the labeled nucleotide can be a non-incorporatable nucleotide. The non-incorporatable nucleotide can bind to the polymerase and template nucleic acid molecule which is base-paired to a polymerization initiation site, in a template-dependent manner, but does not incorporate. Different types of labeled nucleotides can be employed in the method for detecting the presence of a transiently-bound nucleotide in order to determine the frequency, duration, or intensity, of a transiently-bound nucleotide. For example, a comparison can be made between the frequency/duration/intensity of transiently-bound complementary and non-complementary nucleotides. Typically, for direct excitation of the reporter moiety, the length of the transient binding time of a complementary nucleotide can be longer or more frequent compared to that of a non-complementary nucleotide. Typically, for FRET-based excitation and detection of the reporter moieties, the transient binding time of a complementary nucleotide can be of longer duration compared to that of a non-complementary nucleotide.
In one embodiment, the polymerase can be operably linked to an energy transfer donor (e.g., fluorescent dye or nanoparticle). In an example, the labeled nucleotide comprises an energy transfer acceptor moiety (e.g., fluorescent dye). For example, the energy transfer donor and acceptor can be a FRET pair. The signal (or change in the signal) from the energy transfer donor or acceptor can be used to detect the presence of the transiently-bound nucleotide. In a particular example, the signal emitted by the transiently-bound nucleotide can be a FRET signal.
In one embodiment, the excitation source can be electromagnetic radiation. The excitation source can be a laser. The signal, or the change in the signal, can be optically detectable. In an example, the polymerase has an active site. The active site can be enzymatically-active. The labeled nucleotide can bind the active site, thereby bringing the polymerase and labeled nucleotide in close proximity with each other. The polymerase may be labeled or unlabeled. In one embodiment, the signal or change in the signal can be a fluorescent signal resulting from direct excitation of the label which is operably linked to the transiently-bound labeled nucleotide or to the labeled polymerase. In one embodiment, the energy transfer donor or acceptor moieties can fluoresce in response to direct excitation. These fluorescence responses can be a signal or change in a signal. In an example, the energy transfer acceptor moiety can fluoresce in response to energy transferred from a proximal excited energy transfer donor moiety. These fluorescence responses can be a signal or change in a signal. The proximal distance between the donor and acceptor moieties that accommodates energy transfer can be dependent upon the particular donor/acceptor pair. The proximal distance between the donor and acceptor moieties can be about 1-20 nm, or about 1-10 nm, or about 1-5 nm, or about 5-10 nm. The energy transfer signal generated by proximity of the donor moiety to the acceptor moiety can remain unchanged. In another example, the energy transfer signal generated by proximity of the donor moiety to the acceptor moiety results in changes in the energy transfer signal. The changes in the signal or the energy transfer signal from the donor or acceptor moiety can include changes in the: intensity of the signal; duration of the signal; wavelength of the signal; amplitude of the signal; polarization state of the signal; duration between the signals; or rate of the change in intensity, duration, wavelength or amplitude. The change in the signal or the energy transfer signal can include a change in the ratio of the change of the energy transfer donor signal relative to change of the energy transfer acceptor signals. The signal or the energy transfer signal from the donor can increase or decrease. In another example, the signal or the energy transfer signal from the acceptor can increase or decrease. The signal or the energy transfer signal associated with nucleotide transient-binding can include: a decrease in the donor signal when the donor is proximal to the acceptor; an increase in the acceptor signal when the acceptor is proximal to the donor; an increase in the donor signal when the distance between the donor and acceptor increases; or a decrease in the acceptor signal when the distance between the donor and acceptor increases.
In an example, unincorporatable or non-incorporatable nucleotides or analogs thereof may or may not have a structure similar to that of a native nucleotide which may include base, sugar, and phosphate moieties.
The non-incorporatable nucleotides can bind the polymerase/template complex in a template-dependent manner, or can act as a universal mimetic and bind the polymerase/template complex in a non-template-dependent manner. The non-incorporatable nucleotides can be a nucleotide mimetic of incorporatable nucleotides, such as adenosine, guanosine, cytidine, thymidine or uridine nucleotides. The non-incorporatable nucleotide includes any compound having a nucleotide structure, or a portion thereof, which can bind a polymerase.
For example, the non-incorporatable nucleotides can have the general structure:
R11—(—P)n—S—B
Where B can be a base moiety, such as a hetero cyclic base which includes substituted or unsubstituted nitrogen-containing heteroaromatic ring. Where S can be a sugar moiety, such as a ribosyl, riboxyl, or glucosyl group. Where n can be 1-10, or more. Where P can be one or more substituted or unsubstituted phosphate or phosphonate groups. Where R11, if included, can be a reporter moiety (e.g., a fluorescent dye). In one embodiment, the non-incorporatable nucleotide having multiple phosphate or phosphonate groups, the linkage between the phosphate or phosphonate groups can be non-hydrolyzable by the polymerase. The non-hydrolyzable linkages include, but are not limited to, amino, alkyl, methyl, and thio groups. Non-incorporatable nucleotide tetraphosphate analogs can have alpha-thio or alpha boreno substitutions.
The phosphate or phosphonate portion of the non-incorporatable nucleotide can have the general structure:
where B can be a base moiety and S can be a sugar moiety. Where any one of the R1-R7 groups can render the nucleotide non-hydrolyzable by a polymerase. Where the sugar C5 position can be CH2, CH2O, CH═, CHR, or CH2. Where the R1 group can be O, S, CH═, CH(CN), or NH. Where the R2, R3, and R4, groups can independently be O, BH3, or SH. Where the R5 and R6 groups can independently be an amino, alkyl, methyl, thio group, or CHF, CF2, CHBr, CCl2, O—O, or —C≡C—. Where the R7 group can be oxygen, or one or more additional phosphate or phosphonate groups, or can be a reporter moiety. Where R8 can be SH, BH3, CH3, NH2, or a phenyl group or phenyl ring. Where R9 can be SH. Where R10 can be CH3, N3CH2CH2, NH2, ANS, N3, MeO, SH, Ph, F, PhNH, PhO, or RS (where Ph can be a phenyl group or phenyl ring, and F can be a fluorine atom or group). The substituted groups can be in the S or R configuration.
The non-incorporatable nucleotides can be alpha-phosphate modified nucleotides, alpha-beta nucleotide analogs, beta-phosphate modified nucleotides, beta-gamma nucleotide analogs, gamma-phosphate modified nucleotides, caged nucleotides, or di-nucleotide analogs.
In one aspect, nucleotides are compounds that can bind selectively to, or can be polymerized by, a polymerase. Typically, but not necessarily, the polymerase selectively binds the nucleotide and catalyzes polymerization of the nucleotide onto a nucleic acid strand (e.g., nucleotide incorporation). Such nucleotides include not only naturally-occurring nucleotides but also any analogs, regardless of their structure, that can bind selectively to, or can be polymerized by, a polymerase. While naturally-occurring nucleotides typically comprise base, sugar and phosphate moieties, the nucleotides of the present disclosure can include compounds lacking any one, some or all of such moieties.
The nucleotides can be operably linked to a reporter moiety (e.g., labeled nucleotides) or can be un-labeled nucleotides. The nucleotides also include non-incorporatable nucleotides, and terminator nucleotides (e.g., chain terminating nucleotides and reversible terminator nucleotides). The nucleotides can be nucleotide polyphosphate molecules. Examples of nucleotide polyphosphate molecules and nucleoside polyphosphate molecules include ribonucleotides, deoxyribonucleotides, ribonucleotide polyphosphate molecules, deoxyribonucleotide polyphosphate molecules, peptide nucleotides, nucleoside polyphosphate molecules, metallonucleosides, phosphonate nucleosides, and modified phosphate-sugar backbone nucleotides, and any analogs or variants of the foregoing.
The nucleotides typically comprise a chain of phosphorus atoms comprising three, four, five, six, seven, eight, nine, ten or more phosphorus atoms. In some embodiments, the phosphorus chain can be attached to any carbon of a sugar ring, such as the 2, 3, or 5′ carbon. The phosphorus chain can be linked to the sugar with an intervening O or S. One or more phosphorus atoms in the chain can be part of a phosphate group having P and O. In another example, the phosphorus atoms in the chain can be linked together with intervening O, NH, S, methylene, substituted methylene, ethylene, substituted ethylene, CNH2, C(O), C(CH2), CH2CH2, or C(OH)CH2R (where R can be a 4-pyridine or 1-imidazole). In one embodiment, the phosphorus atoms in the chain can have side groups having O, BH3, or S. In the phosphorus chain, a phosphorus atom with a side group other than O can be a substituted phosphate group. The phosphate groups include analogs, such as phosphoramidate, phosphorothioate, phosphorodithioate, and O-methylphosphoroamidite groups. At least one of the phosphate groups can be substituted with a fluoro or chloro group. The phosphate groups can be linked to the sugar moiety by an ester or phosphoramide linkage.
The nucleotides typically comprise a hetero cyclic base which includes substituted or unsubstituted nitrogen-containing parent heteroaromatic ring which is commonly found in nucleic acids, including naturally-occurring, substituted, modified, or engineered variants, or analogs of the same. The base is capable of forming Watson-Crick or Hoogstein hydrogen bonds with an appropriate complementary base. Exemplary bases include, but are not limited to, purines and pyrimidines such as: 2-aminopurine, 2,6-diaminopurine, adenine (A), ethenoadenine, N6-2-isopentenyladenine (6iA), N6-2-isopentenyl-2-methylthioadenine (2ms6iA), N6-methyladenine, guanine (G), isoguanine, N2-dimethylguanine (dmG), 7-methylguanine (7mG), 2-thiopyrimidine, 6-thioguanine (6sG), hypoxanthine and O6-methylguanine; 7-deaza-purines such as 7-deazaadenine (7-deaza-A) and 7-deazaguanine (7-deaza-G); pyrimidines such as cytosine (C), 5-propynylcytosine, isocytosine, thymine (T), 4-thiothymine (4sT), 5,6-dihydrothymine, O4-methylthymine, uracil (U), 4-thiouracil (4sU) and 5,6-dihydrouracil (dihydrouracil; D); indoles such as nitroindole and 4-methylindole; pyrroles such as nitropyrrole; nebularine; inosines; hydroxymethylcytosines; 5-methycytosines; base (Y); as well as methylated, glycosylated, and acylated base moieties; and the like.
The nucleotides typically comprise a suitable sugar moiety, such as carbocyclic moiety, acyclic moieties, and other suitable sugar moieties. The sugar moiety may be selected from the following: ribosyl, 2′-deoxyribosyl, 3′-deoxyribosyl, 2′,3′-dideoxyribosyl, 2′,3′-didehydrodideoxyribosyl, 2′-alkoxyribosyl, 2′-azidoribosyl, 2′-aminoribosyl, 2′-fluororibosyl, 2′-mercaptoriboxyl, 2′-alkylthioribosyl, 3′-alkoxyribosyl, 3′-azidoribosyl, 3′-aminoribosyl, 3′-fluororibosyl, 3′-mercaptoriboxyl, 3′-alkylthioribosyl carbocyclic, acyclic and other modified sugars.
Provided herein are labeled nucleotides which can bind in a template-dependent manner, to a nucleic acid-dependent polymerase. In practicing the methods provided herein, the incorporation of the labeled nucleotides can be inhibited by any reaction condition which permits transient binding of a nucleotide (e.g., complementary or non-complementary) to a polymerase, and inhibits nucleotide incorporation, including: (1) reaction conditions and reagents (e.g., temperature, pH, ionic strength, divalent cations, or time); (2) modified polymerases; (3) modifications of the nucleotide which inhibit incorporation; or (4) non-extendible polymerization initiation site.
The labeled nucleotide can bind the polymerase, which is bound to a base-paired template nucleic acid molecule and polymerization initiation site. The polymerase can interrogate the labeled nucleotide for complementarity with the template nucleotide on the template molecule. The transient-binding time of the complementary labeled nucleotide can be longer compared to the transient-binding time of the non-complementary labeled nucleotide.
The labeled nucleotides comprise a nucleotide operably linked to at least one reporter moiety at any position of the base or sugar, or any of the phosphate groups (alpha, beta, gamma, any phosphate group distal to the sugar moiety, or a terminal phosphate group).
The labeled nucleotide can be a non-incorporatable nucleotide or a terminator nucleotide which is operably linked to at least one reporter moiety. The reporter moiety can be a fluorescent dye, energy transfer dye, or any other type of reporter moiety. The labeled nucleotide can be operably linked to different types of reporter moieties. The same type or different types of reporter moieties can be operably linked to different types of nucleotides, for example, to permit base distinction or identification. A linear or branched linker can be used to attach the nucleotide to the reporter moiety. An intervening linker can connect different reporter moieties to each other or to the nucleotide in any combination of linking arrangements. The labeled nucleotide can be incorporated by a naturally occurring, modified, or engineered nucleic acid-dependent polymerase. The labeled nucleotide can be resistant to degradation by 3′-5′ exonuclease activity of the polymerase.
Useful linking schemes include attaching reporter moieties to oligonucleotides synthesized using phosphoramidate to incorporate amino-modified dT. In one embodiment, the reporter moiety (e.g., fluorophore) can be linked to the base of the nucleotide via a hexylacrylamide linker. In another embodiment, the reporter moiety (e.g., fluorophore) can be linked to the C5 position of the base (e.g., cytosine or uracil) via a hexylacrylamide linker (Molecular Probes, A32763 and A32771), or can be linked to the C5 position of the base (e.g., uracil) via a propargylamino linker. In yet another embodiment, the reporter moiety (fluorophore) can be linked to the N7 position of the base (e.g., guanosine) via a propargylamino linker.
Provided herein are one or more reporter moieties which are operably linked to the labeled nucleotides, terminator nucleotides, non-incorporatable nucleotides, nanoparticles, polymerases, template nucleic acid molecules, primer molecules, surfaces, or oligonucleotides.
The reporter moiety generates, or causes to generate, a detectable signal. Any suitable reporter moiety may be used, including luminescent, photoluminescent, electroluminescent, bioluminescent, chemiluminescent, fluorescent, phosphorescent, chromophore, radioisotope, electrochemical, mass spectrometry, Raman, hapten, affinity tag, atom, or an enzyme. The reporter moiety generates a detectable signal resulting from a chemical or physical change (e.g., heat, light, electrical, pH, salt concentration, enzymatic activity, or proximity events). A proximity event includes two reporter moieties approaching each other, or associating with each other, or binding each other.
The reporter moieties may be selected so that each absorbs excitation radiation or emits fluorescence at a wavelength distinguishable from the other reporter moieties to permit monitoring the presence of different reporter moieties in the same reaction. Two or more different reporter moieties can be selected having spectrally distinct emission profiles, or having minimal overlapping spectral emission profiles.
In one aspect, the signals from the different reporter moieties do not significantly overlap or interfere, by quenching, colorimetric interference, or spectral interference.
The chromophore moiety may be 5-bromo-4-chloro-3-indolyl phosphate, 3-indoxyl phosphate, p-nitrophenyl phosphate, and derivatives thereof, or lactamase or peroxidase based chemistry.
The chemiluminescent moiety may be a phosphatase-activated 1,2-dioxetane compound. The 1,2-dioxetane compound includes disodium 2-chloro-5-(4-methoxyspiro[1,2-dioxetane-3,2′-(5-chloro-)tricyclo[3,3,1-13,7]-decan]-1-yl)-1-phenyl phosphate (e.g., CDP-STAR), chloroadamant-2′-ylidenemethoxyphenoxy phosphorylated dioxetane (e.g., CSPD), and 3-(2′-spiroadamantane)-4-methoxy-4-(3″-phosphoryloxy)phenyl-1,2-dioxetane (e.g., AMPPD).
The fluorescent moiety includes: rhodols; resorufins; coumarins; xanthenes; acridines; fluoresceins; rhodamines; erythrins; cyanins; phthalaldehydes; naphthylamines; fluorescamines; benzoxadiazoles; stilbenes; pyrenes; indoles; borapolyazaindacenes; quinazolinones; eosin; erythrosin; Malachite green; CY dyes (GE Biosciences), including Cy3 (and its derivatives) and Cy5 (and its derivatives); DYOMICS and DYLIGHT dyes (Dyomics) including DY-547, DY-630, DY-631, DY-632, DY-633, DY-634, DY-635, DY-647, DY-649, DY-652, DY-678, DY-680, DY-682, DY-701, DY-734, DY-752, DY-777 and DY-782; Lucifer Yellow; CASCADE BLUE; TEXAS RED; BODIPY (boron-dipyrromethene) (Molecular Probes) dyes including BODIPY 630/650 and BODIPY 650/670; ATTO dyes (Atto-Tec) including ATTO 390, ATTO 425, ATTO 465, ATTO 610 611X, ATTO 610 (N-succinimidyl ester), ATTO 635 (NHS ester); ALEXA FLUORS including ALEXA FLUOR 633, ALEXA FLUOR 647, ALEXA FLUOR 660, ALEXA FLUOR 700, ALEXA FLUOR 750, and ALEXA FLUOR 680 (Molecular Probes); DDAO (7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one or any derivatives thereof) (Molecular Probes); QUASAR dyes (Biosearch); IRDYES dyes (LiCor) including IRDYE 700DX (NHS ester), IRDYE 80016 (NHS ester) and IRDYE 800CW (NHS ester); EVOBLUE dyes (Evotech Biosystems); JODA 4 dyes (Applied Biosystems); HILYTE dyes (AnaSpec); MR121 and MR200 dyes (Roche); Hoechst dyes 33258 and 33242 (Invitrogen); FAIR OAKS RED (Molecular Devices); SUNNYVALE RED (Molecular Devices); LIGHT CYCLER RED (Roche); EPOCH (Glen Research) dyes including EPOCH REDMOND RED (phosphoramidate), EPOCH YAKIMA YELLOW (phosphoramidate), EPOCH GIG HARBOR GREEN (phosphoramidate); Tokyo green; and CF dyes including CF 647 and CF555 (Biotium).
Quencher dyes may include: ATTO 540Q, ATTO 580Q, and ATTO 612Q (Atto-Tec); QSY dyes including QSY 7, QSY 9, QSY 21, and QSY 35 (Molecular Probes); and EPOCH ECLIPSE QUENCHER (phosphoramidate) (Glen Research). The fluorescent moiety can be a 7-hydroxycoumarin-hemicyanine hybrid molecule which is a far-red emitting dye.
The fluorescent moiety may be a fluorescence-emitting metal such as a lanthanide complex, including those of Europium and Terbium.
Provided herein are reporter moieties which can be energy transfer moieties, such as energy transfer pairs (e.g., donors and acceptors), which are operably linked to the labeled nucleotides, terminator nucleotides, non-incorporatable nucleotides, nanoparticles, polymerases, template nucleic acid molecules, primer molecules, surfaces, or oligonucleotides.
In one aspect, the energy transfer moiety can be an energy transfer donor, such as a nanoparticle or an energy transfer dye. In another aspect, the energy transfer moiety can be an energy transfer acceptor, such as an energy acceptor dye.
In one aspect, the energy transfer pair can be operably linked to the same molecule. In another aspect, the donor and acceptor can be operably linked to different molecules in any combination. For example, the donor can be linked to the polymerase, template molecule, or primer molecule, and the acceptor can be linked to the nucleotide (e.g., non-incorporatable nucleotide or terminator nucleotide), the template molecule, or the primer molecule.
The energy transfer donor is capable of absorbing electromagnetic energy (e.g., light) at a first wavelength and emitting excitation energy in response. The energy acceptor is capable of absorbing excitation energy emitted by the donor and fluorescing at a second wavelength in response.
The donor and acceptor moieties can interact with each other physically or optically in a manner which produces a detectable signal when the two moieties are in proximity with each other. A proximity event includes two different moieties (e.g., energy transfer donor and acceptor) approaching each other, or associating with each other, or binding each other.
The donor and acceptor moieties can transfer energy in various modes, including: fluorescence resonance energy transfer (FRET), scintillation proximity assays (SPA), luminescence resonance energy transfer (LRET), direct quenching, chemiluminescence energy transfer (CRET), bioluminescence resonance energy transfer (BRET), and excimer formation.
In one aspect, the energy transfer pair can be FRET donor and acceptor moieties. FRET is a distance-dependent radiationless transmission of excitation energy from a donor moiety to an acceptor moiety. For example, a donor moiety, in an excited state, transfers its energy to a proximal acceptor moiety by non-radiative dipole-dipole interaction or energy transfer not strictly following the Forster's theory, such as nonoverlapping energy transfer occurring when nonoverlapping acceptors are utilized. Typically, the efficiency of FRET energy transmission is dependent on the inverse sixth-power of the separation distance between the donor and acceptor, which is approximately 10-100 Angstroms. FRET is useful for investigating changes in proximity between or within biological molecules. FRET efficiency may depend on donor-acceptor distance r as 1/r6 or 1/r4. The distance where FRET efficiency is 50% is termed R0, also known as the Forster distance. R0 is unique for each donor-acceptor combination and may be about 5 to 10 nm. The efficiency of FRET energy transfer can sometimes be dependent on energy transfer from a point to a plane which varies by the fourth power of distance separation.
In biological applications, FRET can provide an on-off type signal indicating when the donor and acceptor moieties are within proximity of each other. Additional factors affecting FRET efficiency include the quantum yield of the donor, the extinction coefficient of the acceptor, and the degree of spectral overlap between the donor and acceptor. Procedures are well known for maximizing the FRET signal and detection by selecting high yielding donors and high absorbing acceptors with the greatest possible spectral overlap between the two. The change in fluorescence from a donor (e.g., reduced fluorescence signal) during a FRET event, can be an indication of proximity between a donor and acceptor moiety.
The production of signals from FRET donors and acceptors can be sensitive to the distance between donor and acceptor moieties, the orientation of the donor and acceptor moieties, or a change in the environment of one of the moieties. For example, a nucleotide (e.g., non-incorporatable or terminator nucleotide) linked with a FRET moiety (e.g., acceptor) may produce a detectable signal when it approaches, associates with, or binds a polymerase linked to a FRET moiety (e.g., donor). In another example, a FRET donor and acceptor linked to one protein can emit a FRET signal upon conformational change of the protein. Some FRET donor/acceptor pairs exhibit changes in absorbance or emission in response to changes in their environment, such as changes in pH, ionic strength, ionic type (NO2, Ca+2, Mg+2, Zn+2, Na+, Cl−, K+), oxygen saturation, and solvation polarity.
The FRET donor or acceptor may be a fluorophore, luminophore, chemiluminophore, bioluminophore, or quencher. Accordingly, the FRET donor and acceptors may undergo fluorescence or other types of energy transfer with each other, including luminescence resonance energy transfer, bioluminescence resonance energy transfer, chemiluminescence resonance energy transfer, and similar types of energy transfer not strictly following the Forster's theory, such as the non-overlapping energy transfer when non-overlapping acceptors are utilized.
The energy transfer moiety can be a FRET quencher. Typically, quenchers have an absorption spectrum with large extinction coefficients, however the quantum yield for quenchers is reduced, such that the quencher emits little to no light upon excitation. Quenching can be used to reduce the background fluorescence, thereby enhancing the signal-to-noise ratio. In one aspect, energy transferred from the donor may be absorbed by the quencher which emits moderated (e.g., reduced) fluorescence. In another aspect, the acceptor can be a non-fluorescent chromophore which absorbs the energy transferred from the donor and emits heat (e.g., the energy acceptor is a dark quencher).
For an example, a quencher can be used as an energy acceptor with a nanoparticle donor in a FRET system. One exemplary method involves the use of quenchers in conjunction with reporters comprising fluorescent reporter moieties. In this strategy, certain nucleotides in the reaction mixture are labeled with a reporter comprising a fluorescent label, while the remaining nucleotides are labeled with one or more quenchers. Alternatively, each of the nucleotides in the reaction mixture is labeled with one or more quenchers. Discrimination of the nucleotide bases is based on the wavelength or intensity of light emitted from the FRET acceptor, as well as the intensity of light emitted from the FRET donor. If no signal is detected from the FRET acceptor, a corresponding reduction in light emission from the FRET donor indicates transient-binding of the nucleotide labeled with a quencher. The degree of intensity reduction may be used to distinguish between different quenchers.
Examples of fluorescent donors and non-fluorescent acceptor (e.g., quencher) combinations have been developed for detection of proteolysis and nucleic acid hybridization. FRET donors, acceptors and quenchers can be moieties that absorb electromagnetic energy (e.g., light) at about 300-900 nm, or about 350-800 nm, or about 390-800 nm.
Energy transfer donor and acceptor moieties can be made from materials which typically fall into four general categories, including: (1) organic fluorescent dyes, dark quenchers and polymers (e.g., dendrimers); (2) inorganic material such as metals, metal chelates and semiconductors nanoparticles; (3) biomolecules such as proteins and amino acids (e.g., green fluorescent protein and derivatives thereof); and (4) enzymatically catalyzed bioluminescent molecules. The material for making the energy transfer donor and acceptor moieties can be selected from the same or different categories.
The FRET donor and acceptor moieties which are organic fluorescent dyes, quenchers or polymers include traditional dyes that emit in the UV, visible, or near-infrared region. The UV emitting dyes include coumarin-, pyrene-, and naphthalene-related compounds. The visible and near-infrared dyes include xanthene-, fluorescein-, rhodol-, rhodamine-, and cyanine-related compounds. The fluorescent dyes also includes DDAO ((7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one)), resorufin, ALEXA FLUOR and BODIPY dyes (both Molecular Probes), HILYTE Fluors (AnaSpec), ATTO dyes (Atto-Tec), DY dyes (Dyomics GmbH), TAMRA (Perkin Elmer), tetramethylrhodamine (TMR), TEXAS RED, DYLIGHT (Thermo Fisher Scientific), FAM (AnaSpec), JOE and ROX (both Applied Biosystems), and Tokyo Green.
Additional fluorescent dyes which can be used as quenchers includes: DNP, DABSYL, QSY (Molecular Probes), ATTO (Atto-Tec), BHQ (Biosearch Technologies), QXL (AnaSpec), BBQ (Berry and Associates) and CY5Q/7Q (Amersham Biosciences).
The FRET donor and acceptor moieties which comprise inorganic materials include gold (e.g., quencher), silver, copper, silicon, semiconductor nanoparticles, and fluorescence-emitting metal such as a lanthanide complex, including those of Europium and Terbium.
Suitable FRET donor/acceptor pairs include: FAM as the donor and JOE, TAMRA, and ROX as the acceptor dyes. Other suitable pairs include: CYA as the donor and R6G, TAMRA, and ROX as the donor dyes.
In one embodiment, a nucleotide can be operably linked to a suitable reporter moiety. This labeled nucleotide can bind transiently to the polymerase. The reporter moiety can be excited and the signal emitted by the reporter moiety can be detected.
In another embodiment, a polymerase can be operably linked to a suitable nanoparticle and a nucleotide can be operably linked to a suitable reporter moiety. The labeled nucleotide can bind to the polymerase. The nanoparticle can be excited and the resulting energy from the excited nanoparticle can be transferred to the reporter moiety. The transferred energy can excite the reporter moiety, which can be emitted as a detectable signal.
Provided herein are terminator nucleotides which can be incorporated onto the polymerization initiation site, in a template-dependent manner, by a nucleic acid-dependent polymerase, but the terminator nucleotide (which is incorporated) inhibits the incorporation of the next nucleotide. The terminator nucleotide can be incorporated by a naturally occurring, modified, or engineered nucleic acid-dependent polymerase.
The extending strand comprises the polymerization initiation site and a nucleotide which is incorporated at the terminal 3′ end of the initiation site. The extending strand can have an extendible- or non-extendible 3′ terminal end. The extendible end includes a terminal 3′-OH group. The non-extendible end is not extendible by a polymerase. The non-extendible end can include any moiety which inhibits incorporation of the next nucleotide. A terminator nucleotide, which is incorporated onto the polymerization initiation site, forms the new non-extendible end of the extending strand.
The terminator nucleotide comprises a nucleotide operably linked to an inhibitor moiety. The inhibitor moiety comprises any chemical compound or chemical group which permits incorporation of the terminator nucleotide by the polymerase but inhibits incorporation of the next nucleotide. Thus, the polymerase can incorporate one and only one terminator nucleotide, thereby advancing nucleotide incorporation by only one base. The inhibitor moiety can be operably linked to any portion of the nucleoside or nucleotide (e.g., any phosphate group, or base or sugar moiety). The same type or different types of inhibitor moieties can be operably linked to different types of nucleotides. The terminator nucleotide can be resistant to degradation by 3′-5′ exonuclease activity of the polymerase.
On the terminator nucleotide, the inhibitor moiety can be modified so that the next nucleotide can be incorporated (e.g., reversible terminator nucleotide). Alternatively, the inhibitor moiety can be removed (de-blocking) to permit incorporation of the next nucleotide. Accordingly, on a polymerization initiation site which has a terminator nucleotide incorporated onto its 3′ end, the inhibitor moiety can be modified or removed to permit incorporation of the next nucleotide.
In one embodiment, the terminator nucleotides can be non-labeled, or can be operably linked to at least one reporter moiety at any position of the base or sugar, or any of the phosphate groups (alpha, beta, gamma, or terminal phosphate group).
Suitable terminator nucleotides having inhibitor moieties attached to the sugar 3′ position, base-linked dyes, where the linkers are cleavable under the same conditions are useful. Suitable terminator nucleotides having photocleavable linkers are also useful.
The terminator nucleotides comprise a nucleotide operably linked to at least one suitable inhibitor moiety. The inhibitor moiety comprises any chemical compound or chemical group which permits incorporation onto the polymerization initiation site, in a template-dependent manner, by a nucleic acid-dependent polymerase, but inhibits incorporation of the next nucleotide. The inhibitor moiety can modify, substitute, or protect, any portion of the nucleotide (e.g., base, sugar, or phosphate group). A suitable inhibitor moiety can be operably linked to any part of the nucleotide (or nucleoside) including the base or sugar moiety, or any phosphate group. The suitable inhibitor moiety can permit incorporation of the terminator nucleotide, in a polymerase-driven, template-dependent manner, but inhibits, stalls, or slows down incorporation of the next nucleotide by the polymerase. The suitable inhibitor moiety inhibits incorporation of the next nucleotide by physical, chemical, or charge interaction with the polymerase or incoming nucleotide.
The suitable inhibitor moiety can be operably linked to the 2′ or 3′ position of the sugar moiety. In one embodiment, the 2′ or 3′-H or —OH group of the sugar moiety can be modified, substituted, or protected. For example, it is well known that DNA polymerases require a polymerization initiation site having a terminal 3′-OH group. Thus, the inhibitor moiety can be any chemical group or compound, which is not an —OH group, operably linked to the 3′ C of the sugar moiety. In some embodiments, the suitable inhibitor moiety can be an —H group operably linked to the 3′ C of the sugar moiety. Such embodiments include dideoxynucleosides and dideoxynucleotides.
The suitable inhibitor moiety can be operably linked to any position of the nitrogenous base, such as a purine group, including the C2, C4, C5, N3, or C6, of cytosine, thymine, and uracil. The suitable inhibitor moiety can be operably linked to any position of the pyrimidine group, including the C2, C6, C8, N3 and N7 of adenine and guanine.
The suitable inhibitor moiety can be operably linked to any phosphate group, such as the alpha, beta, gamma, or a terminal phosphate group.
In another embodiment, the suitable inhibitor moiety can be linked to any portion of the nucleoside or nucleotide, and sterically hinder the incoming nucleotide. In yet another embodiment, the suitable inhibitor moiety can be a charged group (positive or negative) and linked to any portion of the nucleoside or nucleotide and can inhibit the polymerase from incorporating the next nucleotide. In another embodiment, the suitable inhibitor moiety can be linked to at least one of: a sterically-hindering group, fluorophore, or quencher, in any order and in any combination.
The suitable inhibitor moiety comprises any group including: amine, alkyl, alkenyl, alkynyl, alkyl amide, aryl, ether, ester, benzyl, propargyl, propynyl, phosphate, or analog thereof. For example, the suitable inhibitor moiety can be a 3′-O-allyl moiety.
Suitable inhibitor moieties are well known in the art, and include: fluorenylmethyloxycarbonyl (FMOC), 4-(anisyl)diphenylmethyltrityl (MMTr), dimethoxytrityl (DMTr), monomethoxytrityl, trityl (Tr), benzoyl (Bz), isobutyryl (ib), pixyl (pi), ter-butyl-dimethylsilyl (TBMS), and 1-(2-fluorophenyl)-4-methoxypiperidin 4-yl (FPMP).
The suitable inhibitor moiety can be a reporter moiety (e.g., fluorescent dye) operably linked to the base or sugar moiety. For example, a fluorescent dye operably linked to the base via a 2-nitrobenzyl group, where the 2-nitrobenyl group has the alpha carbon substituted with one alkyl or aryl group. The 2-nitrobenzyl group can be photocleavable.
In another example, the suitable inhibitor moiety can be a reporter moiety (e.g., fluorescent dye, e.g., ALEXA FLUOR 549) operably linked to the 5 position of pyrimidines or the 7 position of the purines, via a cleavable disulfide linker.
In yet another example, the suitable inhibitor moiety can be a rhodamine-type dyes, such as R6G, R110, ROX, or TAMRA, or dichloro-derivatives thereof, which are based-linked dyes, including the commercially-available rhodamine dye terminator nucleotides from Applied Biosystems. The suitable inhibitor moiety can be a charged group (positive or negative) or a group capable of becoming charged, including a carboxylic acid, carboxylated, phosphate, di-phosphate, peptide, dipeptide, sulfate, disulfate, caproic acid, or amino acid (e.g., a negatively charged amino acid such as aspartic acid, glutamic acid, histidine, lysine, or arginine).
The suitable inhibitor moiety can be a non-incorporatable nucleotide or nucleoside which is linked to the base by a tether. The tether can be linked to a fluorescent label. The tether can include a cleavable moiety, such as a disulfide group. The suitable inhibitor moiety can be a hydrocaryldithiomethyl-modified compound. The suitable inhibitor moiety can include an ethyl dithio linker. The suitable inhibitor moiety can be an alkyl chain homologue having any chain length, which can be produced by replacing 2-bromoethanol and ethylsulfide reagents with any alkyl chain homologue. The suitable inhibitor moiety can be any phosphate, SO3, or C(O)R group, or modified groups thereof. In the C(O)R group, R can be an H, alkyl, benzyl, aryl, alkenyl, alkynyl group, any combination thereof.
In one embodiment, removal or modification of the inhibitor moiety which is attached to the 3′ C of the sugar moiety, and restoration of a 3′-OH group, can permit incorporation of a subsequent nucleotide (e.g., reversible terminator nucleotide). In another embodiment, removal or modification of the inhibitor moiety which is attached to the sugar, base, or phosphate group, can permit incorporation of a subsequent nucleotide (e.g., reversible terminator nucleotide).
In one aspect, a suitable linker operably links the terminator nucleotide to the inhibitor moiety. The suitable linker does not interfere with the function or activity of the nucleotide, nucleoside, or inhibitor moiety. The suitable linker can be cleavable or fragmentable to permit removal of the inhibitor moiety. The suitable linker can be the inhibitor moiety. In one embodiment, the nucleotide can be attached directly to the inhibitor moiety without an intervening linker. Various linkers and linker chemistries for generating the terminator nucleotides are disclosed infra.
The terminator nucleotides can be linked to inhibitor moieties using any suitable linking scheme, including linking schemes using amine linkers, or primary or secondary amines, or a rigid hydrocarbon arm.
The terminator nucleotide can include more than one linker, where the linkers are the same or different. The multiple linkers can be removed, cleaved or fragmented using different temperatures, enzymatic activities, chemical agents, or different wavelengths of electromagnetic radiation.
In the terminator nucleotide, the suitable linker can be cleavable by heat, enzymatic activity, chemical agent, or electromagnetic radiation. Cleavable groups include: disulfide, amide, thioamide, ester, thioester, vicinal diol, or hemiacetal. Other cleavable bonds include enzymatically-cleavable bonds, such as peptide bonds (cleaved by peptidases), phosphate bonds (cleaved by phosphatases), nucleic acid bonds (cleaved by endonucleases), and sugar bonds (cleaved by glycosidases).
In one embodiment, the cleavable linker can be a photocleavable linker, such as a 2-nitrobenzyl linker, or others. Analogs of the 2-nitrobenzyl linker, and other photocleavable linkers can be used as cleavable blocking groups, including: 2-nitrobenzyloxycarbonyl (NBOC); nitroveratryl; 1-pyrenylmethyl; 6-nitroveratryloxycarbonyl (NVOC); dimethyldimethoxy-benzyloxycarbonyl (DDZ); 5-bromo-7-nitroindolinyl; O-hydroxy-alpha-methyl-cinnamoyl; methyl-6-nitroveratryloxycarbonyl; methyl-6-nitropiperonyloxycarbonyl; 2-oxymethylene anthraquinone; dimethoxybenzyloxy carbonyl; 5-bromo-7-nitroindolinyl; O-hydroxy-alpha-methyl cinnamoyl; t-butyl oxycarbonyl (TBOC), and 2-oxymethylene anthriquinone. The photocleavable linkers can be illuminated with an electromagnetic source at about 320-800 nm, depending on the particular linker, to achieve cleavage. For example, 1-(2-nitrophenyl)ethyl can be cleaved with light at about 300-350 nm, and 5-bromo-7-nitroindolinyl can be cleaved with light at about 420 nm. In another embodiment, the photocleavable linker can serve as the inhibitor moiety.
In another embodiment, the terminator nucleotide can include two or more cleavable linkers, each attached to a different portion of the nucleotide. For example, the terminator nucleotide can include two different photo-cleavable linkers that are cleavable with the same or different wavelengths of light.
In another embodiment, the linker can be an ethyl dithio or an alkyl chain linker. In another embodiment, the cleavable linker can be a disulfide-linker which is a chemically-cleavable linker. In yet another embodiment, the cleavable linker can be an allyl moiety which is cleavable by palladium (Pd(0)) in a deallylation reaction, or an azidomethyl group which is cleavable with Tris(2-carboxyethyl)phosphine (TCEP) in aqueous solution. In still another embodiment, the linker can be cleavable with silver nitrate (AgNO3). In another embodiment, an azidomethyl group can serve as an inhibitor moiety and a cleavable linker.
A procedure for synthesizing a terminator nucleotide having an unblocked 3′OH group and carrying a biotin molecule linked to the base moiety (N6-alkylated base) via a 2-nitrobenzyl linker can be envisaged.
In the terminator nucleotide, the suitable fragmentable linker is capable of fragmenting in an electronic cascade self-elimination reaction. In some embodiments, the fragmentable linker comprises a trigger moiety. The trigger moiety comprises a substrate that can be cleaved or “activated” by a specified trigger agent. Activation of the trigger moiety initiates a spontaneous rearrangement that results in the fragmentation of the linker and release of the enjoined compound. For example, the trigger moiety can initiate a ring closure mechanism or elimination reaction. Various elimination reactions, include 1,4-, 1,6- and 1,8-elimination reactions.
Any means of activating the trigger moiety may be used. Selection of a particular means of activation, and hence the trigger moiety, may depend, in part, on the particular fragmentation reaction desired. In some embodiments, activation is based upon cleavage of the trigger moiety. The trigger moiety can include a cleavage site that is cleavable by a chemical reagent or enzyme. For example, the trigger moiety can include a cleavage recognition site that is cleavable by a sulfatase (e.g., SO3 and analogs thereof), esterase, phosphatase, nuclease, glycosidase, lipase, esterase, protease, or catalytic antibody.
In an example, photodiodes used for detection can be implemented such that they are fully depleted. Correlated double sampling is used to eliminate thermal noise of the pixel, creating a highly sensitive pixel. Read noise can be less than a few electrons. To increase sensitivity even further, electron-multiplication (EM) gain can be used. The structure to enable EM gain can be implemented in the non-photosensitive area of the pixel. A large electric field can be created between adjacent electrodes after charge is transferred from the photodiode or CCD. As the electric field becomes large enough, impact ionization occurs and the collected electrons are multiplied. This multiplication process allows the pixel to have noise levels less than 1 electron such that the pixel is single photon sensitive. Furthermore, the pixels can be arranged near the polymerase such that no optical occlusions occur in the path of transduction, which can give a 100% fill factor, which allows for high quantum efficiency.
Once polynucleotide targets are localized within the system, solutions including at least one type of labeled nucleotide can be contacted with at least one of the targets. For example, a mixed nucleotide solution including at least two different nucleotide types, each type modified with a different dye having a different fluorescent spectrum, can flow through the flow cell of the sequencing device, as illustrated 4206. In a particular example, a nucleotide solution including four nucleotide types, each type modified with a different associated dye having different emission spectrum, can be applied to the sequencing device. As a result of incorporation of nucleotides along a target polynucleotide, fluorescence can be detected from the fluorescent dye associated with the types of nucleotides, as illustrated at 4208. For example, the solution including at least two dye modified nucleotide types is applied, incorporation of the two different types can be detected based on fluorescence at two different spectrums.
As illustrated 4210, the sequence of nucleotide incorporations associated with fluorescent emissions can be used to determine the base identities of one or more incorporated nucleotides. For example, a base calling subroutine can determine, based on the sequence of detected fluorescent signals detected by a single pixel, a sequence of nucleotide bases along a target polynucleotide.
In another exemplary method illustrated in
The nucleotide solutions each including a different type of dye-modified nucleotide can flow sequentially through the sequencing device, as illustrated at 4306. Optionally, four different nucleotide solutions each including a different type of nucleotide modified with a dye can be utilized sequentially, flowing a different nucleotide solution between flows of a wash solution. Fluorescent emissions emitted as a result of nucleotide incorporation can be detected, as illustrated 4308. In a particular example in which four different nucleotide solutions are utilized, a fluorescent emission can indicate incorporated base based on the solution flowing at the time the emitted fluorescence. As such, a single dye can be used. Alternatively, multiple dyes can be used.
As a result of the detection, a nucleotide sequence can be determined, as illustrated at 4310. The sequence of fluorescent signals associated with the nucleotide solution flowing at time of a fluorescent signal can be utilized to determine the sequence of nucleotides incorporated during template-dependent synthesis driven by a given target polynucleotide that is associated with a single pixel.
Advantageously, a system can be formed without an external microscope objective and EM-CCDs and instead with a CMOS photosensitive substrate. In particular, the system advantageously includes a high density array of incorporation detectors integrated on a CMOS substrate. Optionally, the system includes immobilization of the enzyme, such as a DNA polymerase, at each detector or immobilization of the DNA strand at each detector. Each incorporation detector can contains an integrated radiation source as well as the spectrally sensitive detector. Spectral selectivity can be obtained by multiple confinement wells placed at various depths within the same pixel, can be implemented with permanent use color filter photoresist, or can be implemented with absorption layers tuned with thickness. The excitation light source can be integrated local to each incorporation site and bound within the semiconductor substrate using hot carrier direct recombination. Data for each incorporation site may be limited to 3 bits indicating an incorporation event along with the color.
In some embodiments, the disclosure relates generally to methods, as well as related compositions, systems, apparatuses and devices, for detecting a signal, or a change in a signal, emitted by a labeled nucleotide in a nucleotide incorporation reaction.
In some embodiments, a method for sequencing a target polynucleotide, comprises the steps of: contacting a device with an enzymatic reaction, wherein the enzymatic reaction includes contacting: (i) a polymerase with (ii) at least one target polynucleotide which is base paired with a primer and with (iii) at least one type of a nucleotide having an optically detectable moiety, thereby incorporating a nucleotide onto the primer, wherein the device comprises any of the integrated devices described herein that have detectors that detect signals from a nucleotide incorporation reaction. The method further comprises the steps of: generating an optically detectable signal by exciting the optically detectable moiety with an excitation source; and detecting the optically detectable signal. The method further comprises the steps of: identifying the incorporated nucleotide.
In some embodiments, a method for sequencing a target polynucleotide further comprises a second enzymatic reaction including the steps of: contacting the device with a second enzymatic reaction, wherein the second enzymatic reaction includes contacting: (i) a second polymerase with (ii) the at least one target polynucleotide which is base paired with the primer and with (iii) at least one type of a nucleotide having an optically detectable moiety, thereby incorporating a second nucleotide onto the primer. The method can further comprise the steps of: generating a second optically detectable signal by exciting the second optically detectable moiety with an excitation source; and detecting the second optically detectable signal. The method further comprises the steps of: identifying the incorporated nucleotide.
Alternatively, the method for sequencing further comprises a different second enzymatic reaction, comprising: contacting the device with a second enzymatic reaction, wherein the second enzymatic reaction includes contacting: (i) a second polymerase with (ii) the at least one target polynucleotide which is base paired with the primer and with (iii) at least one type of a nucleotide lacking an optically detectable moiety, thereby incorporating onto the primer the at least one type of nucleotide lacking an optically detectable moiety. This embodiment is known as “dark” sequencing.
In some embodiments, a method for sequencing a target polynucleotide further comprises a third enzymatic reaction including the steps of: contacting the device with a third enzymatic reaction, which includes at least one type of a second nucleotide lacking an optically detectable moiety; and incorporating onto the primer the second nucleotide lacking the optically detectable moiety.
Alternatively, the method for sequencing further comprises a different third enzymatic reaction, comprising: contacting the device with a third enzymatic reaction, wherein the enzymatic reaction includes at least one type of a nucleotide having an optically detectable moiety; and generating a second optically detectable signal by exciting the optically detectable moiety with an excitation source; detecting the second optically detectable signal; and identifying the second incorporated nucleotide.
In some embodiments, a method for sequencing a target polynucleotide further comprises a fourth enzymatic reaction including the steps of: contacting the device with a fourth enzymatic reaction, wherein the enzymatic reaction includes at least one type of a nucleotide having an optically detectable moiety; generating a second optically detectable signal by exciting the optically detectable moiety with an excitation source; detecting the second optically detectable signal; and identifying the second incorporated nucleotide.
In some embodiments, any combination of the first, second, third and fourth nucleic sequencing reactions can be conducted with (i) at least one type of nucleotide linked to an optically-detectable moiety such as an energy transfer acceptor moiety, and (ii) a polymerase linked to an energy transfer donor moiety. In some embodiments, any combination of the first, second, third and fourth nucleic sequencing reactions can be conducted with a mutant polymerase having altered nucleotide incorporation kinetics, which include: altered polymerase binding to the target molecule, altered polymerase binding to the nucleotide, altered polymerase catalyzing nucleotide incorporation, altered the polymerase cleaving the phosphate group or substituted phosphate group, or altered polymerase releasing the cleavage product.
In some embodiments, the disclosure relates generally to methods, as well as related compositions, systems, apparatuses and devices, for generating an energy transfer signal comprising the steps of: contacting a device with an enzymatic reaction, where the enzymatic reaction includes contacting: (i) a polymerase linked to an energy transfer donor moiety with (ii) a target nucleic acid molecule which is base-paired with a primer and with (iii) at least one type of a nucleotide having an energy transfer acceptor moiety, thereby incorporating the nucleotide onto the primer, and locating the polymerase and the at least one type of nucleotide in close proximity with each other to generate an energy transfer signal, wherein the device comprises any of the integrated devices described herein that have detectors that detect signals from a nucleotide incorporation reaction.
In some embodiments, for energy transfer sequencing methods, the polymerase is a mutant polymerase having altered nucleotide incorporation kinetics. In some embodiments, the mutant polymerase has altered nucleotide incorporation kinetics, which include: altered polymerase binding to the target molecule, altered polymerase binding to the nucleotide, altered polymerase catalyzing nucleotide incorporation, altered the polymerase cleaving the phosphate group or substituted phosphate group, or altered polymerase releasing the cleavage product (see e.g., U.S. published application No. 2012/0322057, published Dec. 20, 2012, hereby incorporated by reference in its entirety). In some embodiments, the energy transfer donor moiety comprises a nanoparticle (U.S. Pat. No. 8,603,792, issued Dec. 10, 2013, to Nikiforov, hereby incorporated by reference in its entirety). In some embodiment, the sequencing reaction is conducted with a single target nucleic acid molecule (target polynucleotide). In some embodiments, the mutant polymerase comprises the amino acid sequence found in any of SEQ ID NOS:1-3 of U.S. published application No. 2012/0329042, published Dec. 27, 2012 (hereby incorporated by reference in its entirety).
In some embodiments, the disclosure relates generally to methods, as well as related compositions, systems, apparatuses and devices, for detecting a signal, or a change in a signal, emitted by a labeled nucleotide which is transiently-bound to a polymerase and the template nucleotide. The detected signal can be used to identify the transiently-bound nucleotide and deduce the identity of the bound nucleotide.
The methods can be practiced using any suitable reaction condition comprising reagents and components which mediate polymerase-dependent reactions, including: forming the complex (template molecule/initiation site/polymerase); transient-binding a labeled nucleotide to a polymerase in a template-dependent manner (without nucleotide incorporation); and detecting the signal (or change in a signal) from the transiently-bound labeled nucleotide. The methods can include a separate step for incorporating a nucleotide. In some embodiments, transiently-binding a nucleotide to a polymerase, without polymerizing, includes not forming a covalent bond between the transiently bound nucleotide and a free 3?-OH end of a primer or nucleic acid molecule. The methods can be practiced using one or more different types of polymerases. For example, the methods can be practiced using one type of polymerase for the transient-binding step, and the same or different type of polymerase for the nucleotide incorporation step. The methods can be practiced using one or more different types of nucleotides. The methods can be practiced using separate, step-wise reactions: contacting, binding, detecting, incorporating, or removing.
The transient-binding methods can be performed on any type of polymerase-dependent platform, including: single molecule, arrays of single molecules, populations of immobilized template molecules (i.e., multiple copies of the same template molecule immobilized on a device, support, solid surface or bead, etc), direct excitation/detection, FRET-based excitation/detection, fluorescence polarization, non-immobilized polymerase/template complex, or any combination thereof (see U.S. Pat. No. 8,632,975, issued on Jan. 21, 2014 to Vander Horn, hereby incorporated by reference in its entirety).
In some embodiments, methods for transiently binding a nucleotide to a polymerase can be conducted under any reaction condition which permits the polymerase to selectively bind a complementary nucleotide, but incorporation of the complementary nucleotide is perturbed, impeded, or inhibited. Such reaction conditions include utilizing: (1) any reaction conditions and reagents, such as temperature, pH, ionic strength, multivalent cations, or time; (2) any polymerase which selectively binds a complementary nucleotide but exhibits reduced nucleotide incorporation activity; (3) non-incorporatable nucleotides; or (4) a non-extendible polymerization initiation site. Any combination of these reaction conditions can be practiced in any order in the transient-binding methods provided herein.
In some embodiments, methods for detecting the presence of a transiently-bound nucleotide comprise the steps of: (a) contacting a device with an enzymatic reaction, wherein the enzymatic reaction comprises: contacting at least one type of a labeled nucleotide to a complex having a first polymerase bound to at least one target polynucleotide that is bound to a primer, under suitable conditions to transiently-bind, without polymerizing, the at least one type of labeled nucleotide to the polymerase in a nucleic acid template-dependent manner; (b) detecting the transiently-bound labeled nucleotide; and (c) identifying the labeled nucleotide transiently-bound to the polymerase, wherein the device comprises any of the integrated devices described herein that have detectors that detect signals from a nucleotide incorporation reaction. The steps (a)-(c) can be repeated at least once. In some embodiments, the method further comprises the steps of: (d) removing the transiently-bound nucleotide; and (e) contacting the complex with at least one type of a second nucleotide under suitable conditions for a second polymerase to polymerize the second nucleotide. The steps (d)-(e) can be repeated at least once. The steps (a)-(e) can be repeated at least once.
In some embodiments, the suitable conditions for transiently-binding a nucleotide include conducting the enzymatic reaction in the presence of a cation that inhibits nucleotide incorporation by the polymerase. In some embodiments, the labeled nucleotide comprises a nucleotide linked to an optically detectable moiety. In some embodiments, the methods include: generating an optically detectable signal by exciting the optically detectable moiety with an excitation source; and detecting the optically detectable signal. In some embodiments, the methods further comprise: identifying the incorporated nucleotide (the second nucleotide). In some embodiments, the incorporated nucleotide produces a nucleotide incorporation byproduct. The nucleotide incorporation byproduct includes pyrophosphate, hydrogen ions or protons. In some embodiments, the methods further comprise: detecting the nucleotide incorporation byproduct. In some embodiment, the sequencing reaction is conducted with a single target nucleic acid molecule (target polynucleotide).
In some embodiments, methods for detecting the presence of a transiently-bound nucleotide comprise the steps of: (a) contacting a device with an enzymatic reaction, wherein the enzymatic reaction comprises: contacting at least one type of a labeled nucleotide to a complex which comprises a polymerase bound to a template nucleic acid molecule which is base-paired to a primer having a polymerization initiation site, under conditions suitable to transiently-bind the labeled nucleotide to the polymerase in a template-dependent manner but inhibits incorporation of the nucleotide; (b) exciting the labeled nucleotide or the polymerase with an excitation source; and (c) detecting a signal, or a change in a signal, emitted by the transiently-bound labeled nucleotide in step (a), thereby detecting the presence of the transiently-bound nucleotide, wherein the device comprises any of the integrated devices described herein that have detectors that detect signals from a nucleotide incorporation reaction. In some embodiments, methods further comprise the step: (d) identifying the nucleotide transiently-bound to the polymerase. The steps (a)-(c) can be repeated at least once. The steps (a)-(d) can be repeated at least once.
In one embodiment, the methods for identifying a nucleotide bound to a polymerase, further comprises the steps of: (e1) removing the transiently-bound nucleotide; and (f1) contacting the complex with at least one type of nucleotide under suitable conditions for the polymerase to polymerize the nucleotide. In this embodiment, the same polymerase in step (a) is contacted in step (f1). The steps (e1)-(f1) can be repeated at least once. The steps (a)-(f1) can be repeated at least once. In some embodiments, the incorporated nucleotide produces a nucleotide incorporation byproduct. The nucleotide incorporation byproduct includes pyrophosphate, hydrogen ions or protons. In some embodiments, the methods further comprise: detecting the nucleotide incorporation byproduct.
In another embodiment, the methods for identifying a nucleotide bound to a polymerase, further comprises the steps of: (e2) removing the first polymerase and the transiently-bound nucleotide so that the template nucleic acid molecule, nucleic acid primer molecule or self-priming template nucleic acid molecule remains immobilized to the surface; (f2) binding the remaining template nucleic acid molecule with a second polymerase; and (g2) contacting the second polymerase with at least one type of nucleotide under suitable conditions for the second polymerase to polymerize the nucleotide. In this embodiment, the polymerase in step (a) is different from the polymerase in step (f2). The steps (e2)-(g2) can be repeated at least once. The steps (a)-(g2) can be repeated at least once. In some embodiments, the incorporated nucleotide produces a nucleotide incorporation byproduct. The nucleotide incorporation byproduct includes pyrophosphate, hydrogen ions or protons. In some embodiments, the methods further comprise: detecting the nucleotide incorporation byproduct.
In one embodiment, the suitable conditions to transiently bind the nucleotide to the polymerase in step (a1) or (a2) comprise: (i) reducing the levels or omission of a cation that permits nucleotide incorporation or addition of a cation that inhibits nucleotide incorporation; (ii) the polymerase selectively binds the nucleotide in a template-dependent manner and exhibits reduced nucleotide incorporation activity; (iii) the at least one type of labeled nucleotide is a labeled non-incorporatable nucleotide; or (iv) the polymerization initiation site is a non-extendible polymerization initiation site. Any combination of these suitable conditions can be practiced to identify the nucleotide bound to the polymerase.
In another embodiment, the suitable conditions in step (a) comprise: (i) cations present at a concentration that inhibits nucleotide incorporation; (ii) the polymerase selectively binds the nucleotide in a template-dependent manner and exhibits reduced nucleotide incorporation activity; (iii) the at least one type of labeled nucleotide is a labeled non-incorporatable nucleotide; or (iv) the polymerization initiation site is a non-extendible polymerization initiation site.
In one embodiment, the cation that inhibits nucleotide incorporation can be calcium, scandium, titanium, vanadium, chromium, iron, cobalt, nickel, copper, zinc, gallium, germanium, arsenic, selenium, rhodium, or strontium.
In another embodiment, the suitable conditions for polymerizing the nucleotide in step (f1) or (g2) comprise: (i) including a cation that permits nucleotide incorporation or reducing the levels or omission of a cation that inhibits nucleotide incorporation; (ii) using a polymerase which selectively binds the nucleotide in a template-dependent manner and polymerizes the bound nucleotide; (iii) using at least one type of incorporatable nucleotide; or (iv) using a polymerization initiation site having an extendible polymerization initiation site. In some embodiments, cations that permit nucleotide incorporation include magnesium and manganese.
In one embodiment, suitable conditions for incorporating the terminator nucleotide in any of steps (a) and (k) can include a manganese or magnesium compound, or the manganese or magnesium compound can be omitted. In another embodiment, the manganese compound can be MnCl2. In another embodiment, the magnesium compound can be MgCl2. In another embodiment, the amount of manganese or magnesium compound can be about 1-5 mM, or about 2-5 mM. In another embodiment, the manganese or magnesium compound can be washed away or chelated after any of the steps.
In some embodiments, the polymerase can be an RB69, Phi29, B103 polymerase, or a Klenow fragment. In some embodiments, the polymerase can exhibit exonuclease activity. In another embodiment, the polymerase can be any 9° N polymerase or derivative thereof, including THERMINATOR, THERMINATOR II, or THERMINATOR-GAMMA polymerase (New England Biolabs, catalog # s M0261L, M0266L, and M0334L, respectively). In another embodiment, the second polymerase can be the same type or a different type as the first polymerase. In some embodiments, the polymerase comprise a mutant polymerase, that can have altered nucleotide incorporation kinetics. In some embodiments, the altered nucleotide incorporation kinetics include: altered polymerase binding to the target molecule, altered polymerase binding to the nucleotide, altered polymerase catalyzing nucleotide incorporation, altered the polymerase cleaving the phosphate group or substituted phosphate group, or altered polymerase releasing the cleavage product. In some embodiments, the polymerase comprises the amino acid sequence found in any of SEQ ID NOS: 1-8 found in U.S. published application No. 2010/031114, published Dec. 9, 2010 (hereby incorporated by reference in its entirety).
In some embodiments, any of the nucleic acid sequencing methods described herein include an enzyme that catalyzes polymerization of a nucleotide in a template-dependent manner, including a DNA-dependent polymerase, RNA-dependent polymerase, or a reverse transcriptase. In some embodiments, the polymerase can be a wild-type (e.g., native) or modified/mutant polymerase. In some embodiments, the polymerase can be a thermolabile or thermostable polymerase. In some embodiments, the polymerase lacks exonuclease activity. In some embodiments, the polymerase can bind a labeled nucleotide. In some embodiments, the polymerase can bind an incorporatable or a non-incorporatable nucleotide. In some embodiments, the first or the second polymerase can be operably linked to a reporter moiety (e.g., energy transfer donor moiety).
In some embodiments, any of the nucleic acid sequencing methods described herein include an energy transfer donor moiety, such as a fluorescent dye or nanoparticle (U.S. Pat. No. 8,603,792, issued Dec. 10, 2013, to Nikiforov, hereby incorporated by reference in its entirety). In some embodiments, the nanoparticle comprises an inorganic fluorescent nanoparticle. In some embodiments, the nanoparticle is 1-20 nm in its largest dimension. In some embodiments, the nanoparticle is a non-blinking nanoparticle.
In some embodiments, any of the nucleic acid sequencing methods described herein include a template polynucleotide, which includes a DNA molecule, RNA molecule, or DNA/RNA hybrid molecule. The template polynucleotide comprises a single template nucleic acid molecule or a plurality of template nucleic acid molecules. The plurality of template nucleic acid molecules (target polynucleotides) comprises a population of nucleic acids having different sequences or having substantially identical sequences.
In some embodiments, any of the nucleic acid sequencing methods described herein include a primer having a polymerization initiation site at the 3′ terminal end. The primer can be hybridized to the template polynucleotide. The primer can be a self-priming template nucleic acid molecule. In another embodiment, the polymerization initiation site can be base-paired to the template nucleic acid molecule. In another embodiment, the polymerization initiation site can be an extendible terminal 3′OH group or a non-extendible terminal group. In another embodiment, the polymerization initiation site can be a terminal 3′OH group of the nucleic acid primer molecule or a terminal 3′OH group of a self-priming template nucleic acid molecule.
In some embodiments, any of the nucleic acid sequencing methods described herein include one or more nucleic acid molecules attached (immobilized) to a device, support, surface or microsphere. For example, a template polynucleotide, nucleic acid primer molecule, or self-priming template polynucleotide, can be immobilized to a device, support, surface or microsphere. In some embodiments, the device is any integrated device described herein, including those having detectors that detect signals from a nucleotide incorporation reaction. In some embodiments, the support includes a particle or microsphere.
In some embodiments, any of the nucleic acid sequencing methods described herein include at least one type of nucleotide. The nucleotide can be adenosine, guanosine, cytosine, thymidine, uridine or inosine. In some embodiments, the nucleotide includes 3-10 phosphate groups, or more.
In some embodiments, any of the nucleic acid sequencing methods described herein can be conducted with one type of nucleotide, or no more than two different types of nucleotides, or no more than three different types of nucleotides, or no more than four different types of nucleotides, or more than four different types of nucleotides.
In some embodiments, the nucleotide can be non-labeled, or can be linked to at least one reporter moiety. The reporter moiety includes any optically detectable moiety, such as a fluorophore, energy transfer donor moiety or energy transfer acceptor moiety. In some embodiments, the optically detectable moiety is photobleachable. In some embodiments, the optically-detectable moiety is attached to any portion of the nucleotide, including the base, sugar (e.g., 2′ or 3′ position) or phosphate backbone. The optically detectable moiety is attached to the nucleotide by a linker. In some embodiments, the linker is cleavable with light, heat, a chemical compound or an enzyme. In some embodiments, the cleavable linker can be cleaved with light, heat, a chemical compound or an enzyme.
In some embodiments, the energy transfer donor reporter moiety can be an inorganic nanoparticle or a fluorophore. The energy transfer acceptor moiety can be a fluorophore (e.g., fluorescent dye). The energy transfer donor reporter moiety can be linked to the polymerase or nucleotide. The energy transfer acceptor reporter moiety can be linked to the polymerase or nucleotide. In conducting any of the sequencing methods described herein, as an example, a donor-labeled polymerase binds an acceptor-labeled nucleotide, thereby bringing the polymerase and nucleotide in close proximity to permit energy transfer from the donor to the acceptor and generation of an energy transfer signal. Upon excitation from an excitation source (e.g., electromagnetic energy), the acceptor moiety emits a fluorescent signal.
The nucleotide can be incorporatable or non-incorporatable by a polymerase. The non-incorporatable nucleotide can bind to the polymerase and template nucleic acid molecule which can be base-paired to a polymerization initiation site, in a template-dependent manner, but does not incorporate.
In some embodiments, any of the nucleic acid sequencing methods described herein include at least one nucleotide linked to at least one inhibitor moiety to generate a terminator nucleotide. The inhibitor moiety (e.g., blocking moiety) can permit incorporation of the terminator nucleotide but inhibits incorporation of a subsequent nucleotide. The inhibitor moiety can be linked to any portion of the nucleotide including the base, sugar (e.g., 2′ or 3′ position) or phosphate backbone. The inhibitor moiety can be linked to the nucleotide by a cleavable linker that is cleavable with an enzyme, heat, chemical compound, or light. In another embodiment, the inhibitor moiety can be removed via an enzymatic, heat, chemical or light cleavage reaction.
In some embodiments, any of the nucleic acid sequencing methods described herein include at least one nucleotide that is a dideoxyribonucleotide.
In some embodiments, any of the nucleic acid sequencing methods described herein can be conducted by contacting a polymerase with a mixture of nucleotides. The mixture can include different types of nucleotides that differ from each other in their base, sugar or phosphate backbone. The mixture can include only labeled nucleotides, or only non-labeled nucleotides, or at least one labeled (e.g., optically detectable moiety) and at least one non-labeled nucleotide. The mixture can include two, three, four, or more different types of nucleotides. For example, the mixture can include: (i) one type of nucleotide having an optically detectable moiety and two or three different types of nucleotides that lack an optically detectable moiety; or (ii) two different types of nucleotides having different optically detectable moieties and one or two different types of nucleotides that lack an optically detectable moiety; or (iii) three different types of nucleotides having different optically detectable moieties and one type of nucleotide that lacks an optically detectable moiety. In conducting a nucleic acid sequencing reaction, the polymerase can be contacted with the different types of nucleotide in the mixture of nucleotides essentially simultaneously or sequentially.
In some embodiments, any of the nucleic acid sequencing methods described herein include an excitation source for exciting the optically-detectable moiety. The excitation source includes electromagnetic energy or light.
In some embodiments, any of the nucleic acid sequencing methods described herein can be conducted on a single site on a device, or at a plurality of sites on the device. The plurality of sites on the device can be arranged in an organized or random array. The plurality of sites on the device can be arranged in rectilinear or hexagonal pattern.
In some embodiments, any of the nucleic acid sequencing methods described herein can be conducted in a massively parallel manner. The nucleic acid sequencing reactions can be conducted by subjecting a plurality of target polynucleotides to the same enzymatic reaction in parallel, wherein the plurality of target polynucleotides comprises a population of nucleic acids having substantially identical sequences or different sequences.
In some embodiments, any of the nucleic acid sequencing methods described herein include nucleotide incorporation reactions which produce one or more nucleotide incorporation byproducts resulting from the polymerase catalyzing nucleotide polymerization. In some embodiments, nucleotide incorporation byproducts include pyrophosphate molecules, hydrogen ions, or protons.
In some embodiments, any of the nucleic acid sequencing methods described herein can be conducted by flowing reagents to the surface of the integrated device, where the flow contains at least one reagent for conducting nucleic acid sequencing reactions, including polymerases, one type of nucleotides or a mixture of different types of nucleotides, cations that inhibit nucleotide incorporation, cations that permit nucleotide incorporation, and cleaving agents. The flow can deliver to the surface of the device multiple different reagents sequentially or essentially simultaneously.
Each of the above sequencing techniques can be used in conjunction with embodiments of the above described devices and systems.
In a first aspect, a device includes a transparent layer defining a surface exposed to a flow volume and to secure a target polynucleotide template and a detector structure in optical communication with and secured to the transparent layer and including a plurality of detectors configured to detect a fluorescent signal emitted during nucleotide incorporation during template-dependent nucleic acid synthesis.
In an example of the first aspect, the detector structure includes a plurality of pixels, each pixel of the plurality of pixels including at least two detectors of the plurality of detectors. For example, the at least two detectors are disposed adjacent one anther within a plan view. In another example, the at least two detectors are disposed one over the other when viewed in cross-section. In a further example, each pixel includes at least three detectors. For example, each pixel can include at least four detectors.
In another example of the first aspect and the above examples, the transparent layer includes an energy propagation layer.
In a further example of the first aspect and the above examples, the device further includes an energy propagation layer disposed between the transparent layer and the detector structure. For example, the energy propagation layer includes a total internal reflection layer. In another example, the device further includes an energy emitting component to provide energy to the energy propagation layer.
In an additional example of the first aspect and the above examples, the device further includes a separator structure extending from the detector structure toward the transparent layer, the separator structure opaque to the fluorescent signal.
In another example of the first aspect and the above examples, the device further includes a filter layer disposed between the device structure and the transparent layer. For example, the filter layer is configured to limit transmission of excitation energy. In another example, the filter layer is configured to permit the transmission of a wavelength spectrum associated with a dye.
In a further example of the first aspect and the above examples, the device further includes a well structure defining wells disposed on the transparent layer opposite the detector structure.
In an additional example of the first aspect and the above examples, the device further includes a pad structure disposed on the transparent layer opposite the detector structure.
In another example of the first aspect and the above examples, the device further includes a lid, the flow volume defined between the lid and the transparent layer.
In a further example of the first aspect and the above examples, the transparent layer comprises an electrode.
In a second aspect, an apparatus includes a transparent layer defining a surface exposed to a flow volume and to secure a target polynucleotide template; an energy propagation layer disposed opposite the surface of the transparent layer to propagate photonic energy along a path parallel to the surface; an excitation filter layer secured to the energy propagation layer opposite the transparent layer, the excitation filter layer opaque to the photonic energy; and a detector structure secured to the excitation filter layer opposite the energy propagation layer, the detector structure defining a plurality of pixels, each pixel including a detector, each pixel of the plurality of pixels uniquely optically associated with a well of the plurality of wells.
In an example of the second aspect, each pixel includes at least two detectors. For example, the at least two detectors can be disposed adjacent one another within a plan view. In another example, the at least two detectors are disposed one over the other when viewed in cross-section. In an additional example, each pixel includes at least three detectors. For example, each pixel can include at least four detectors. In a further example, the energy propagation layer includes a total internal reflection layer. For example, the apparatus can further include an energy emitting component to provide energy to the energy propagation layer.
In another example of the second aspect and the above examples, the apparatus can further include a separator structure extending from the detector structure toward the transparent layer.
In a further example of the second aspect and the above examples, the apparatus can further include a filter layer disposed between the device structure and the transparent layer, wherein the filter layer is configured to permit the transmission of a wavelength spectrum associated with a dye.
In an additional example of the second aspect and the above examples, the apparatus can further include a well structure defining wells disposed on the transparent layer opposite the detector structure.
In another example of the second aspect and the above examples, the apparatus further includes a pad structure disposed on the transparent layer opposite the detector structure.
In a further example of the second aspect and the above examples, the apparatus further includes a lid, the flow volume defined between the lid and the transparent layer.
In an additional example of the second aspect and the above examples, the transparent layer comprises an electrode.
In a third aspect, an apparatus includes a transparent layer defining a surface exposed to a flow volume and to secure a target polynucleotide; a well structure defining a plurality of wells that expose the transparent layer; an energy propagation layer disposed opposite the surface of the transparent layer and the well structure; an excitation filter layer secured to the energy propagation layer opposite the transparent layer; a color filter layer secured to the excitation filter layer opposite the energy propagation layer; a detector structure secured to the color filter layer opposite the excitation filter layer, the detector structure defining a plurality of pixels, each pixel including at least two detectors, each pixel of the plurality of pixels uniquely optically associated with a well of the plurality of wells; and a plurality of opaque structures disposed between pixels and extending from the detector structure toward the transparent layer.
In a fourth aspect, a system includes a fluidics system including a valve structure and a plurality of reagent containers; a computational system including a controller; and an integrated device. The integrated device includes a transparent layer defining a surface exposed to a flow volume and to secure a target polynucleotide; and a detector structure secured to the transparent layer and including a plurality of detectors to detect a fluorescent signal emitted during nucleotide incorporation using the target polynucleotide as a template, wherein the fluidics system is in communication with the flow volume, and wherein the controller is in communication with the detector structure.
In a fifth aspect, a method of obtaining sequence information from a polynucleotide target includes applying a sequencing device to a sequencing system, the sequencing device defining a flow volume and including a transparent layer including a surface exposed to the flow volume and a detector structure disposed on an opposite side of the transparent layer from the flow volume; applying a polynucleotide to the sequencing device; incorporating at least one nucleotide into a nascent nucleic acid molecule using the polynucleotide as a template; and detecting a fluorescent signal with the detector structure, the fluorescent signal indicative of nucleotide incorporation.
In an example of the fifth aspect, the nucleotide solution includes at least two dye modified nucleotide types.
In another example of the fifth aspect or the above examples, the nucleotide solution includes four different dye modified nucleotide types.
In a further example of the fifth aspect or the above examples, applying the nucleotide solution includes sequentially applying at least two different nucleotide solutions.
In a sixth aspect, a method for sequencing a target polynucleotide includes contacting the device of any one of the first, second, or third aspects or examples thereof with an enzymatic reaction, wherein the enzymatic reaction includes contacting: (i) a polymerase with (ii) at least one target polynucleotide which is base paired with a primer and with (iii) at least one type of a nucleotide having an optically detectable moiety, thereby incorporating a nucleotide onto the primer.
In an example of the sixth aspect, the method further includes a) generating an optically detectable signal by exciting the optically detectable moiety with an excitation source; and b) detecting the optically detectable signal.
In another example of the sixth aspect and the above examples, the method further includes identifying the incorporated nucleotide.
In a further example of the sixth aspect and the above examples, the method further includes contacting the device with a second enzymatic reaction, wherein the second enzymatic reaction includes contacting: (i) a second polymerase with (ii) the at least one target polynucleotide which is base paired with the primer and with (iii) at least one type of a nucleotide having an optically detectable moiety, thereby incorporating a second nucleotide onto the primer.
In an additional example of the sixth aspect and the above examples, the method further includes a) generating a second optically detectable signal by exciting the second optically detectable moiety with an excitation source; and b) detecting the second optically detectable signal.
In another example of the sixth aspect and the above examples, the method further includes identifying the second incorporated nucleotide.
In a further example of the sixth aspect and the above examples, the method further includes contacting the device with a second enzymatic reaction, wherein the second enzymatic reaction includes contacting: (i) a second polymerase with (ii) the at least one target polynucleotide which is base paired with the primer and with (iii) at least one type of a nucleotide lacking an optically detectable moiety, thereby incorporating onto the primer the at least one type of nucleotide lacking an optically detectable moiety. For example, the method further includes a) contacting the device with a third enzymatic reaction, which includes at least one type of a second nucleotide lacking an optically detectable moiety; and b) incorporating onto the primer the second nucleotide lacking the optically detectable moiety.
In an additional example of the sixth aspect and the above examples, the method further includes a) repeating the step of contacting the device with a third enzymatic reaction, wherein the enzymatic reaction includes at least one type of a nucleotide having an optically detectable moiety; b) generating a second optically detectable signal by exciting the optically detectable moiety with an excitation source; c) detecting the second optically detectable signal; and d) identifying the second incorporated nucleotide.
In another example of the sixth aspect and the above examples, the method further includes a) contacting the device with a third enzymatic reaction, wherein the enzymatic reaction includes at least one type of a nucleotide having an optically detectable moiety; b) generating a second optically detectable signal by exciting the optically detectable moiety with an excitation source; c) detecting the second optically detectable signal; and d) identifying the second incorporated nucleotide.
In a seventh aspect, a method for generating an energy transfer signal includes contacting the above devices with a enzymatic reaction, wherein the enzymatic reaction includes contacting: (i) a mutant polymerase having altered nucleotide incorporation kinetics and linked to an energy transfer donor moiety with (ii) a target polynucleotide which is base paired with a primer and with (iii) at least one type of a nucleotide having an energy transfer acceptor moiety, thereby incorporating a nucleotide onto the primer, and locating the polymerase and the at least one type of nucleotide in close proximity with each other to generate the energy transfer signal, wherein the altered nucleotide incorporation kinetics includes altered polymerase binding to the target molecule, altered polymerase binding to the nucleotide, altered polymerase catalyzing nucleotide incorporation, altered the polymerase cleaving the phosphate group or substituted phosphate group, or altered polymerase releasing the cleavage product.
In an example of the sixth and seventh aspects, the associated examples, and the above examples, the first polymerase and the second polymerase are the same type or different types of polymerases.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the second polymerase and the third polymerase are the same type or different types of polymerases. For example, the third polymerase and the fourth polymerase are the same type or different types of polymerases.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the first, second, third or fourth polymerase is a DNA-dependent polymerase, RNA-dependent polymerase, or reverse transcriptase. For example, the first, second, third or fourth polymerase is a mutant polymerase. In another example, the first, second, third or fourth polymerase has altered nucleotide incorporation kinetics. For example, the altered nucleotide incorporation kinetics includes altered polymerase binding to the target molecule, altered polymerase binding to the nucleotide, altered polymerase catalyzing nucleotide incorporation, altered the polymerase cleaving the phosphate group or substituted phosphate group, or altered polymerase releasing the cleavage product.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the first, second, third or fourth polymerase is linked to an energy transfer donor moiety. For example, the energy transfer donor moiety is a nanoparticle or a fluorescent dye. In a particular example, the nanoparticle is an inorganic fluorescent nanoparticle.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one target polynucleotide is a single nucleic acid molecule or a plurality of target polynucleotides. For example, the plurality of target polynucleotides comprises a population of nucleic acids having different sequences or having substantially identical sequences.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one target polynucleotide is RNA or DNA.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one target polynucleotide or the primer is attached to the device. For example, the at least one target polynucleotide or the primer is attached the transparent layer.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one target polynucleotide or the primer is attached to a support. For example, the support is a particle or microsphere. In another example, the plurality of nucleic acid molecules have different sequences or have substantially identical sequences.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide comprises one type of nucleotide, or no more than two different types of nucleotides, or no more than three different types of nucleotides, or no more than four different types of nucleotides.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of second nucleotide comprises one type of nucleotide, or no more than two different types of nucleotides, or no more than three different types of nucleotides, or no more than four different types of nucleotides.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide is adenosine, guanosine, cytosine, thymidine, uridine or inosine.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide is adenosine, guanosine, cytosine, thymidine, uridine or inosine.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide comprises 3-10 or more phosphate groups.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide comprises 3-10 or more phosphate groups. For example, the different types of nucleotides differ from each other in their base, sugar or phosphate backbone.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide comprises a non-incorporatable nucleotide.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the optically detectable moiety is linked to any one of the phosphate groups, the base or the sugar of the at least one type of nucleotide.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the optically detectable moiety is linked to the nucleotide via a linker that is cleavable with light, a chemical compound or an enzyme. For example, the method further includes removing the optically detectable moiety by cleaving the cleavable linker with light, a chemical compound or an enzyme.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the optically detectable moiety is a fluorophore.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the optically detectable signal comprises a fluorescent signal.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of a nucleotide is linked to an optically detectable moiety comprising an energy transfer acceptor moiety.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of a nucleotide is linked to an energy transfer acceptor moiety and the first, second or third polymerase is linked to an energy transfer donor moiety, and incorporating the at least one type of nucleotide onto the primer, brings the first, second or third polymerase and the at least one type of a nucleotide into close proximity with each other to generate an energy transfer signal. For example, the energy transfer signal comprises a fluorescent signal.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of nucleotide is linked to at least one inhibitor moiety that inhibits incorporation of a subsequent nucleotide. For example, the inhibitor moiety is linked to the nucleotide at any position of the base, or any position of the sugar. In another example, the inhibitor moiety is linked to the nucleotide via a linker that is cleavable with light, a chemical compound or an enzyme. For example, the method further includes removing the inhibitor moiety by cleaving the cleavable linker with light, a chemical compound or an enzyme.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the at least one type of a nucleotide having an optically detectable moiety comprises a mixture of different types of nucleotides containing at least one type of a nucleotide having an optically detectable moiety and at least one type of nucleotide lacking an optically detectable moiety. For example, the mixture of different types of nucleotides includes two, three, four or more different types of nucleotides. In an example, the different nucleotides in the mixture of nucleotides are contacted sequentially with the first, second or third polymerase. For example, the different nucleotides in the mixture of nucleotides are contacted essentially simultaneously with the first, second or third polymerase. In a further example, the mixture of different types of nucleotides includes: (iv) one type of nucleotide having an optically detectable moiety and two or three different types of nucleotides that lack an optically detectable moiety; or (v) two different types of nucleotides having different optically detectable moieties and one or two different types of nucleotides that lack an optically detectable moiety; or (vi) three different types of nucleotides having different optically detectable moieties and one type of nucleotide that lacks an optically detectable moiety. In another example, the mixture of different types of nucleotides includes a non-incorporatable nucleotide.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the excitation source is electromagnetic energy. For example, the electromagnetic energy is light.
In an additional example of the sixth and seventh aspects, the associated examples, and the above examples, the device comprises a plurality of sites on the device arranged in an organized or random array.
In another example of the sixth and seventh aspects, the associated examples, and the above examples, the device comprises a plurality of sites on the device arranged in a rectilinear or hexagonal pattern.
In a further example of the sixth and seventh aspects, the associated examples, and the above examples, the method further includes subjecting a plurality of target polynucleotides to the same enzymatic reaction in parallel, wherein the plurality of target polynucleotides comprises a population of nucleic acids having substantially identical sequences or different sequences.
In an example of the sixth and seventh aspects, the associated examples, and the above examples, the target polynucleotide comprises a single nucleic acid molecule.
In an eighth aspect, a method for sequencing a target polynucleotide includes contacting the device of any one of the first, second, or third aspects with an enzymatic reaction, wherein the enzymatic reaction includes: contacting at least one type of a labeled nucleotide to a complex having a first polymerase bound to at least one target polynucleotide that is bound to a primer, under suitable conditions to transiently-bind, without polymerizing, the at least one type of labeled nucleotide to the polymerase in a nucleic acid template-dependent manner; detecting the transiently-bound labeled nucleotide; and identifying the labeled nucleotide transiently-bound to the polymerase,
In an example of the eighth aspect, the method further includes removing the transiently-bound nucleotide; and contacting the complex with at least one type of a second nucleotide under suitable conditions for a second polymerase to polymerize the nucleotide.
In another example of the eighth aspect and the above examples, the at least one target polynucleotide comprises a single nucleic acid molecule.
In a further example of the eighth aspect and the above examples, the suitable conditions in the first step include: (i) reducing the levels or omission of a cation that permits nucleotide incorporation or addition of a cation that inhibits nucleotide incorporation; (ii) the polymerase selectively binds the nucleotide in a template-dependent manner and exhibits reduced nucleotide incorporation activity; (iii) the at least one type of labeled nucleotide is a labeled non-incorporatable nucleotide; or (iv) the primer includes a non-extendible polymerization initiation site.
In an additional example of the eighth aspect and the above examples, the suitable conditions in step (a) comprise: (i) cations present at a concentration that inhibits nucleotide incorporation; (ii) the polymerase selectively binds the nucleotide in a template-dependent manner and exhibits reduced nucleotide incorporation activity; (iii) the at least one type of labeled nucleotide is a labeled non-incorporatable nucleotide; or (iv) the primer includes a non-extendible polymerization initiation site. For example, the cation that inhibits nucleotide incorporation is calcium, scandium, titanium, vanadium, chromium, iron, cobalt, nickel, copper, zinc, gallium, germanium, arsenic, selenium, rhodium, or strontium.
In a ninth aspect, a method for nucleic acid sequencing includes contacting the device of any one of the first, second, and third aspects with an enzymatic reaction, wherein the enzymatic reaction includes: transiently binding, without polymerizing, at least a first type of a labeled nucleotide to a first polymerase in the presence of a cation that inhibits nucleotide incorporation by the polymerase, wherein the first polymerase is bound to at least one target polynucleotide that is bound to a primer, and wherein the first type of nucleotide includes an optically detectable moiety; detecting the first type of transiently-bound nucleotide; and identifying the first type of transiently-bound nucleotide,
In an example of the ninth aspect, the method further includes removing the transiently-bound first type of nucleotide; and contacting the complex with at least one type of a second nucleotide under suitable conditions for a second polymerase to polymerize the second type of nucleotide in a template-dependent manner.
In another example of the ninth aspect and the above examples, the at least one target polynucleotide comprises a single nucleic acid molecule.
In a further example of the ninth aspect and the above examples, the suitable conditions in the second step further include any one or more of the following: (i) including a cation that permits nucleotide incorporation or reducing the levels or omission of a cation that inhibits nucleotide incorporation; (ii) the first polymerase selectively binds the second type of nucleotide in a template-dependent manner and polymerizes the bound second type of nucleotide; (iii) the second type of nucleotide is an incorporatable nucleotide; and (iv) the primer is an extendible polymerization initiation site. For example, the cation that inhibits nucleotide incorporation is calcium, scandium, titanium, vanadium, chromium, iron, cobalt, nickel, copper, zinc, gallium, germanium, arsenic, selenium, rhodium, or strontium.
In an additional example of the ninth aspect and the above examples, the first and second polymerases are the same polymerase, or different polymerases of the same type, or different types of polymerases.
In another example of the ninth aspect and the above examples, the first or second polymerase is a DNA-dependent polymerase, RNA-dependent polymerase, or reverse transcriptase.
In a further example of the ninth aspect and the above examples, the first or second polymerase is a mutant polymerase.
In an additional example of the ninth aspect and the above examples, the first or second polymerase has altered nucleotide incorporation kinetics. For example, the altered nucleotide incorporation kinetics includes altered polymerase binding to the target molecule, altered polymerase binding to the nucleotide, altered polymerase catalyzing nucleotide incorporation, altered the polymerase cleaving the phosphate group or substituted phosphate group, or altered polymerase releasing the cleavage product.
In another example of the ninth aspect and the above examples, the first or second polymerase comprises an RB69 polymerase, phi29 polymerase, B103 polymerase, or Klenow fragment polymerase.
In a further example of the ninth aspect and the above examples, the first or second polymerase is linked to an energy transfer donor moiety. For example, the energy transfer donor moiety is a nanoparticle or a fluorescent dye. In an example, the nanoparticle is an inorganic fluorescent nanoparticle.
In an additional example of the ninth aspect and the above examples, the at least one target polynucleotide is a single nucleic acid molecule or a plurality of target polynucleotides. For example, the plurality of target polynucleotides comprises a population of nucleic acids having different sequences or having substantially identical sequences.
In another example of the ninth aspect and the above examples, the at least one target polynucleotide is RNA or DNA.
In a further example of the ninth aspect and the above examples, the at least one target polynucleotide or the primer is attached to the device. For example, the at least one target polynucleotide or the primer is attached the transparent layer of the device.
In an additional example of the ninth aspect and the above examples, the at least one target polynucleotide or the primer is attached to a support.
In another example of the ninth aspect and the above examples, the support is a particle or microsphere.
In a further example of the ninth aspect and the above examples, the labeled nucleotide comprises one type of nucleotide, or no more than two different types of nucleotides, or no more than three different types of nucleotides, or no more than four different types of nucleotides.
In an additional example of the ninth aspect and the above examples, the at least one type of second nucleotide comprises one type of nucleotide, or no more than two different types of nucleotides, or no more than three different types of nucleotides, or no more than four different types of nucleotides.
In another example of the ninth aspect and the above examples, the labeled nucleotide is adenosine, guanosine, cytosine, thymidine, uridine or inosine.
In a further example of the ninth aspect and the above examples, at least one type of a second nucleotide is adenosine, guanosine, cytosine, thymidine, uridine or inosine.
In an additional example of the ninth aspect and the above examples, the labeled nucleotide comprises 3-10 or more phosphate groups.
In another example of the ninth aspect and the above examples, at least one type of a second nucleotide comprises 3-10 or more phosphate groups.
In a further example of the ninth aspect and the above examples, the nucleotide comprises a non-incorporatable nucleotide.
In an additional example of the ninth aspect and the above examples, the labeled nucleotide is linked to at least one optically detectable moiety.
In another example of the ninth aspect and the above examples, the at least one type of a second nucleotide is linked to at least one optically detectable moiety
In a further example of the ninth aspect and the above examples, the at least one optically detectable moiety is linked to any one of the phosphate groups, the base or the sugar of the nucleotide.
In an additional example of the ninth aspect and the above examples, the optically detectable moiety is linked to the nucleotide via a linker that is cleavable with light, a chemical compound or an enzyme. For example, the optically detectable moiety is a fluorophore. In another example, the optically detectable moiety emits a fluorescent signal. In a further example, the optically detectable moiety comprises an energy transfer acceptor moiety.
In another example of the ninth aspect and the above examples, the labeled nucleotide is linked to an energy transfer acceptor moiety and the first polymerase is linked to an energy transfer donor moiety, and the transient binding the nucleotide to the polymerase brings the first polymerase and the labeled nucleotide in close proximity with each other to generate an energy transfer signal. For example, the energy transfer signal comprises a fluorescent signal.
In a further example of the ninth aspect and the above examples, the labeled nucleotide is linked to at least one inhibitor moiety that inhibits incorporation of a subsequent nucleotide. For example, the inhibitor moiety is linked to the nucleotide at any position of the base or the sugar. In an example, the inhibitor moiety is linked to the nucleotide via a linker that is cleavable with light, a chemical compound or an enzyme.
In an additional example of the ninth aspect and the above examples, the labeled nucleotide comprises a mixture of different types of nucleotides containing at least one type of a nucleotide having an optically detectable moiety and at least one type of nucleotide lacking an optically detectable moiety. For example, the mixture of different types of nucleotides includes two, three, four or more different types of nucleotides. In an example, the different nucleotides in the mixture of nucleotides are contacted sequentially with the first polymerase. In another example, the different nucleotides in the mixture of nucleotides are contacted essentially simultaneously with the first polymerase. In an additional example, the mixture of different types of nucleotides includes: (iv) one type of nucleotide having an optically detectable moiety and two or three different types of nucleotides that lack an optically detectable moiety; or (v) two different types of nucleotides having different optically detectable moieties and one or two different types of nucleotides that lack an optically detectable moiety; or (vi) three different types of nucleotides having different optically detectable moieties and one type of nucleotide that lacks an optically detectable moiety. In a further example, the mixture of different types of nucleotides includes a non-incorporatable nucleotide.
In another example of the ninth aspect and the above examples, the method further includes a) generating an optically detectable signal by exciting the optically detectable moiety with an excitation source; and b) detecting the optically detectable signal. For example, the excitation source is electromagnetic energy. In an example, the electromagnetic energy is light.
In a further example of the ninth aspect and the above examples, the device comprises a plurality of sites on the device arranged in an organized or random array.
In an additional example of the ninth aspect and the above examples, the device comprises a plurality of sites on the device arranged in a rectilinear or hexagonal pattern.
In another example of the ninth aspect and the above examples, the method further includes subjecting a plurality of target polynucleotides to the same enzymatic reaction in parallel, wherein the plurality of target polynucleotides comprises a population of nucleic acids having substantially identical sequences or different sequences.
In an tenth aspect, a method for sequencing a target polynucleotide includes contacting the device of any one of the first, second or third aspects with an enzymatic reaction, wherein the enzymatic reaction includes: forming a reaction mixture containing a polymerase and a target polynucleotide, wherein the reaction mixture includes a concentration of cation at which nucleotide polymerization by the polymerase is inhibited; contacting, within the reaction mixture, a first type of nucleotide containing a detectable moiety with the polymerase and transiently binding the first type of nucleotide to the polymerase in a template-dependent manner without polymerizing the transiently bound nucleotide at the primer by the polymerase; detecting a signal generated by the detectable moiety while the first type of nucleotide is transiently bound to the polymerase; removing the transiently bound nucleotide from the polymerase; and contacting the polymerase with a second type of nucleotide and polymerizing the second type of nucleotide at the primer using the polymerase.
In an example of the tenth aspect, wherein the forming in the first step includes any one or more of the following: (i) reducing the levels or omission of a cation that permits nucleotide incorporation or addition of a cation that inhibits nucleotide incorporation.
In another example of the tenth aspect and the above examples, the suitable conditions in step comprise any one or more of the following: (i) including a cation that permits nucleotide incorporation or reducing the levels or omission of a cation that inhibits nucleotide incorporation; (ii) using a first polymerase which selectively binds the second type of nucleotide in a template-dependent manner and polymerizes the bound second type of nucleotide; (iii) using a second type of nucleotide which includes an incorporatable nucleotide; or (iv) using a primer having an extendible polymerization initiation site
In a further example of the tenth aspect and the above examples, the cation that inhibits nucleotide incorporation is calcium, scandium, titanium, vanadium, chromium, iron, cobalt, nickel, copper, zinc, gallium, germanium, arsenic, selenium, rhodium, or strontium.
In an additional example of the tenth aspect and the above examples, the transiently binding in step (b) includes contacting the polymerase with a sufficient amount of a divalent cation to inhibit nucleotide incorporation by the first polymerase. For example, the divalent cation includes calcium.
In another example of the tenth aspect and the above examples, the method further includes repeating the first three steps at least once.
In a further example of the tenth aspect and the above examples, the method includes repeating the fourth and fifth steps at least once.
Note that not all of the activities described above in the general description or the examples are required, that a portion of a specific activity may not be required, and that one or more further activities may be performed in addition to those described. Still further, the order in which activities are listed are not necessarily the order in which they are performed.
In the foregoing specification, the concepts have been described with reference to specific embodiments. However, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the invention as set forth in the claims below. Accordingly, the specification and figures are to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of invention.
As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of features is not necessarily limited only to those features but may include other features not expressly listed or inherent to such process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive-or and not to an exclusive-or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
Also, the use of “a” or “an” are employed to describe elements and components described herein. This is done merely for convenience and to give a general sense of the scope of the invention. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.
Benefits, other advantages, and solutions to problems have been described above with regard to specific embodiments. However, the benefits, advantages, solutions to problems, and any feature(s) that may cause any benefit, advantage, or solution to occur or become more pronounced are not to be construed as a critical, required, or essential feature of any or all the claims.
After reading the specification, skilled artisans will appreciate that certain features are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination. Further, references to values stated in ranges include each and every value within that range.
Claims
1. A device comprising:
- a transparent layer defining a surface exposed to a flow volume and to secure a target polynucleotide template; and
- a detector structure in optical communication with and secured to the transparent layer and including a plurality of detectors configured to detect a fluorescent signal emitted during nucleotide incorporation during template-dependent nucleic acid synthesis, wherein the detector structure includes a plurality of pixels, each pixel of the plurality of pixels including a set of detectors of the plurality of detectors, wherein the set of detectors are defined within the semiconductor structure by a p-type substrate, a deep n-type implant, a shallow n-type implant, and a p-type implant disposed over the shallow n-type implant.
2. The device of claim 1, wherein each pixel of the plurality of pixels includes at least two detectors of the plurality of detectors.
3. The device of claim 2, where the at least two detectors are disposed one over the other when viewed in cross-section.
4. The device of claim 2, wherein each pixel includes at least four detectors.
5. The device of claim 1, wherein the transparent layer includes an energy propagation layer.
6. The device of claim 1, further comprising an energy propagation layer disposed between the transparent layer and the detector structure.
7. The device of claim 6, wherein the energy propagation layer includes a total internal reflection layer.
8. The device of claim 6, further comprising an energy emitting component to provide energy to the energy propagation layer.
9. The device of claim 1, further comprising a separator structure extending from the detector structure toward the transparent layer, the separator structure opaque to the fluorescent signal.
10. The device of claim 1, further comprising a filter layer disposed between the device structure and the transparent layer.
11. The device of claim 10, wherein the filter layer is configured to limit transmission of excitation energy.
12. The device of claim 1, further comprising a well structure defining wells disposed on the transparent layer opposite the detector structure.
13. The device of claim 1, further comprising a lid, the flow volume defined between the lid and the transparent layer.
14. A method of obtaining sequence information from a polynucleotide target, the method comprising:
- applying a sequencing device to a sequencing system, the sequencing device defining a flow volume and including a transparent layer including a surface exposed to the flow volume and a detector structure disposed on an opposite side of the transparent layer from the flow volume, the detector structure including a plurality of detectors configured to detect a fluorescent signal emitted during nucleotide incorporation during template-dependent nucleic acid synthesis, wherein the detector structure includes a plurality of pixels, each pixel of the plurality of pixels including a set of detectors of the plurality of detectors, wherein the set of detectors are defined within the semiconductor structure by a p-type substrate, a deep n-type implant, a shallow n-type implant, and a p-type implant disposed over the shallow n-type implant;
- applying a polynucleotide to the sequencing device;
- incorporating at least one dye modified nucleotide into a nascent nucleic acid molecule using the polynucleotide as a template; and
- detecting a fluorescent signal with the detector structure from a dye of the at least one dye modified nucleotide, the fluorescent signal indicative of nucleotide incorporation of the at least one dye modified nucleotide.
15. The method of claim 14, wherein the nucleotide solution includes at least two dye modified nucleotide types.
16. The method of claim 14, wherein the nucleotide solution includes four different dye modified nucleotide types.
17. The method of claim 14, wherein applying the nucleotide solution includes sequentially applying at least two different nucleotide solutions.
18. The method of claim 14, wherein the transparent layer includes an energy propagation layer, the method further comprising applying excitation energy to the energy propagation layer, the excitation energy exiting the dye of the at least one dye modified nucleotide.
19. The method of claim 18, wherein the sequencing device further includes a filter layer disposed between the device structure and the transparent layer, wherein the filter layer is configured to limit transmission of excitation energy to the plurality of detectors.
20. The method of claim 14, wherein the sequencing device further includes a well structure defining wells disposed on the transparent layer opposite the detector structure, wherein applying a polynucleotide to the sequencing device includes applying the polynucleotides into the wells.
Type: Application
Filed: Mar 25, 2020
Publication Date: Sep 3, 2020
Inventors: William M. LAFFERTY (Encinitas, CA), Jonathan M. ROTHBERG (Guilford, CT), Keith G. FIFE (Palo Alto, CA)
Application Number: 16/830,076
